Gram-negative bacteria and their lipopolysaccharides in Alzheimer’s disease: pathologic roles and therapeutic implications

Hyeon soo Kim; Sujin Kim; Soo Jung Shin; Yong Ho Park; Yunkwon Nam; Chae won Kim; Kang won Lee; Sung-Min Kim; In Duk Jung; Hyun Duk Yang; Yeong-Min Park; Minho Moon

doi:10.1186/s40035-021-00273-y

. 2021 Dec 7;10:49. doi: 10.1186/s40035-021-00273-y

Gram-negative bacteria and their lipopolysaccharides in Alzheimer’s disease: pathologic roles and therapeutic implications

Hyeon soo Kim ^1,^#, Sujin Kim ^1,^2,^#, Soo Jung Shin ^1,^#, Yong Ho Park ^1,^#, Yunkwon Nam ¹, Chae won Kim ¹, Kang won Lee ¹, Sung-Min Kim ³, In Duk Jung ³, Hyun Duk Yang ^4,^✉, Yeong-Min Park ^3,^5,^✉, Minho Moon ^1,^2,^✉

PMCID: PMC8650380 PMID: 34876226

Abstract

Alzheimer’s disease (AD) is the most serious age-related neurodegenerative disease and causes destructive and irreversible cognitive decline. Failures in the development of therapeutics targeting amyloid-β (Aβ) and tau, principal proteins inducing pathology in AD, suggest a paradigm shift towards the development of new therapeutic targets. The gram-negative bacteria and lipopolysaccharides (LPS) are attractive new targets for AD treatment. Surprisingly, an altered distribution of gram-negative bacteria and their LPS has been reported in AD patients. Moreover, gram-negative bacteria and their LPS have been shown to affect a variety of AD-related pathologies, such as Aβ homeostasis, tau pathology, neuroinflammation, and neurodegeneration. Moreover, therapeutic approaches targeting gram-negative bacteria or gram-negative bacterial molecules have significantly alleviated AD-related pathology and cognitive dysfunction. Despite multiple evidence showing that the gram-negative bacteria and their LPS play a crucial role in AD pathogenesis, the pathogenic mechanisms of gram-negative bacteria and their LPS have not been clarified. Here, we summarize the roles and pathomechanisms of gram-negative bacteria and LPS in AD. Furthermore, we discuss the possibility of using gram-negative bacteria and gram-negative bacterial molecules as novel therapeutic targets and new pathological characteristics for AD.

Supplementary Information

The online version contains supplementary material available at 10.1186/s40035-021-00273-y.

Keywords: Alzheimer’s disease, Gram-negative bacteria, Lipopolysaccharide, Exotoxin, Amyloid beta, Tau

Introduction

Alzheimer's disease (AD), one of the main causes of dementia, is a neurodegenerative disease causing cognitive decline and impairment of memory, language, and attention [1]. Previous studies have demonstrated that amyloid-β (Aβ) and tau are pathological hallmarks and primary causes of AD [2]. Medications targeting Aβ and tau have been developed to treat AD; however, they have not been effective in clinical trials. Therefore, changes in therapeutic targets are required, and upstream pathogenic contributors that affect Aβ and tau pathology are receiving increasing interest [3–5]. Many studies regarding the relationships between microbes and AD have indicated microorganisms as one of the new therapeutic targets for AD [6–8]. Namely, extensive changes in the microbiome occur in AD, and studies analyzing the intestinal microbiome in AD patients and animal models have provided interesting insights [9, 10].

Various sources of infection, such as fungi, viruses, and bacteria, are reportedly associated with AD [7]. The occurrence of microbiome dysbiosis or infection of several species of toxic bacteria may contribute to AD pathogenesis by triggering strong inflammatory responses or participating in Aβ production [11, 12]. Surprisingly, systemic inflammatory responses due to bacterial infection may also continue, causing neuronal cell death and Aβ/tau accumulation, contributing to the development and progression of AD. The brains of AD patients contain 5–10 times more bacteria than healthy brains; differences in the distribution and composition of the bacteria have also been studied [13]. In addition, it has been reported that the gram-negative bacteria can cross the blood–brain barrier (BBB) and contribute to neuroinflammation, Aβ accumulation, and tau hyperphosphorylation within the brain [14]. In particular, several gram-negative bacteria, such as Proteobacteria and Chlamydophila pneumonia, have been reported to provoke strong systemic inflammation and contribute to AD pathogenesis [15, 16]. Furthermore, the byproducts of gram-negative bacteria, such as lipopolysaccharides (LPS), capsular proteins, fimbrillins and flagellins, can also penetrate the brain and affect neuroinflammation, and Aβ and tau pathology [17].

LPS is a macromolecule mainly distributed in the outer membrane of gram-negative bacteria and acts as a powerful endotoxin [18]. The immune system responds with high sensitivity to LPS, high concentrations of which can cause sepsis and septic shock [19]. Furthermore, sepsis caused by LPS is a risk factor for cognitive impairment and AD development [20, 21]. Interestingly, LPS concentration in the plasma of patients with AD is 3–6 times higher than normal; similarly, LPS concentration in the blood of AD animal models is approximately 3 times higher than normal [18, 22, 23]. In AD, the LPS-induced pro-inflammatory immunomodulation is suggested to have a fatal effect on AD pathology [24]. Furthermore, a vicious cycle involving infectious species and their products in the induction of AD pathology has been continually proposed as an ‘infection hypothesis’ that potentially provides interesting insights into AD pathology [5, 17, 25]. These pieces of evidence suggest that LPS could not only be one of the upstream pathologic processes that either initiate or induce AD pathology, but also a promising therapeutic target for AD treatment.

Despite accumulating evidence on the importance of gram-negative bacteria and their LPS in AD pathology, their pathogenic mechanisms have not been clarified. Therefore, we attempted to summarize the pathogenic roles of gram-negative bacteria and their LPS in AD pathology and discuss their potential as effective therapeutic targets for AD (Additional file 1: Fig. S1).

Pathomechanisms of gram-negative bacteria in AD

Alteration of gram-negative bacteria in AD

With a growing interest in the importance of intestinal bacteria in AD pathology, an increasing number of studies have found links among gut microbiota, infectious microbes, and AD pathogenesis. Particularly, gram-negative bacteria are associated with the onset of AD. Various studies have demonstrated a positive association between gram-negative bacteria, such as Helicobacter pylori (H. pylori), Porphyromonas gingivalis (P. gingivalis), Prevotella melaninogenica, and Campylobacter rectus, and incidence of AD [26–30]. Moreover, some studies showed that the presence of gram-negative bacteria is directly associated with AD mortality [27, 30, 31]. Surprisingly, there are many studies pointing to the changes in gram-negative bacterial composition in animal models and patients with AD (Tables 1 and 2). In 8-month-old amyloid precursor protein/presenilin 1 (APP/PS1) mice, the proportion of Bacteroidetes at the phylum level increases, while Allobaculum and Akkermansia decrease at the genus level; concurrently, there is an increase in Rikenellaceae and S24-7 [32] (Table 1). In addition, another study demonstrated that Helicobacteraceae and Desulfovibrionaceae at the family level are significantly higher in APP/PS1 mice than in wild-type (WT) mice [33]. At the genus level, Helicobacter and Odorivacter are significantly abundant in APP/PS1 mice, while Prevotella abundance is remarkably higher in WT mice. In APP/PS1 mice, the proportion of Bacteroidetes tends to increase as AD progresses [34]. In the case of 5×FAD mice, it has been confirmed that the distribution of intestinal gram-negative bacteria starts to change at 9 weeks compared to that in WT mice. The proportion of Bacteroidetes in 5×FAD mice tends to decrease at 9-week-old and 18-week-old compared to 3-week-old in 5×FAD mice. These results indicated that the proportion of gram-negative bacteria changes with AD progression in 5×FAD mice [35]. Furthermore, it is known that the distribution of intestinal gram-negative bacteria in healthy individuals differs from that in AD patients, and the distribution of intestinal gram-negative bacteria changes as AD progresses. Some analyses of microorganisms in blood and feces showed that patients with AD have changed populations of gram-negative bacteria, such as Spirochetes, Chlamydia, Proteobacteria, Firmicutes, Bacteroidetes, and Actinobacteria at the phylum level (Table 2). In particular, it has been confirmed that the population of Firmicutes and Bifidobacterium decreases and the population of Bacteroidetes increases in the feces of patients with AD, compared with healthy controls [9]. Surprisingly, gram-negative bacteria found in the peripheral nervous system have also been observed in the central nervous system (CNS) in patients with AD [13, 36–39]. The gram-negative bacteria that show changes in the proportion and population within the brain and cerebrospinal fluid (CSF) of patients with AD are Chlamydia, Proteobacteria, Bacteroidetes, and Spirochetes [13, 15, 38, 40–49]. These results suggest that the gram-negative bacteria in the peripheral system can penetrate the BBB and infiltrate the brain.

Table 1.

Species of gram-negative bacteria exhibiting alteration in animal models of Alzheimer’s disease

Source	Subject	Method	Gram-negative bacteria						References
Source	Subject	Method	Phylum	Class	Order	Family	Genus	Species	References
Feces	APP/PS1 mice	PCR	Proteobacteria			Helicobacteraceae Desulfovibrionaceae	Helicobacter		[33]
		PCR	Bacteroidetes	Bacteroidia	Bacteroidales	Porphyromonoadaceae	Odoribacter		[33]
		PCR	Bacteroidetes						[50]
		PCR	Bacteroidetes						[32]
			Bacteroidetes	Bacteroidia	Bacteroidales	Rikenellaceae
			Bacteroidetes	Bacteroidia	Bacteroidales	S24-7
			Verrucomicrobia	Verrucomicrobiae	Verrucomicrobiales	Akkermansiaceae	Akkermansia
		PCR	Bacteroidetes						[34]
	5×FAD mice	PCR	Proteobacteria	δ-, γ-, ε-Proteobacteria		Helicobacteriaceae, Pseudomonadaceae			[23]
		PCR	Bacteroidetes	Bacteroidia	Bacteroidia	Prevotellaceae			[23]
		PCR	Bacteroidetes						[35]
		PCR	Bacteroidetes	Bacteriodia	Bacteroidales	Muribaculaceae			[10]
	5×FAD mice 3×Tg mice	PCR	Bacteroidetes						[51]
	5×FAD mice 3×Tg mice	PCR	Proteobacteria						[51]

Open in a new tab

PCR Polymerase chain reaction

Table 2.

Species of gram-negative bacteria exhibiting alteration in patients with Alzheimer’s disease

	Subject	Source	Method	Gram-negative bacteria						References
	Subject	Source	Method	Phylum	Class	Order	Family	Genus	Species	References
Peripheral system	AD patients	Blood	ELISA	Spirochetes	Spirochetes	Spirochetes	Spirochetaceae	Borrelia	Borrelia burgdorferi	[52]
				Chlamydia	Chlamydiae	Chlamydiales	Chlamydiaceae	Chlamydophila	Chlamydia pneumoniae
				Proteobacteria	Epsilonproteobacteria	Campylobacterales	Helicobacteraceae	Helicobacter	Helicobacter pylori
			WB	Spirochetes	Spirochetes	Spirochetes	Spirochetaceae	Borrelia	Borrelia burgdorferi	[53]
			ELISA WB	Spirochetes	Spirochetes	Spirochetes	Spirochetaceae	Borrelia	Borrelia burgdorferi	[46]
		Feces	PCR	Firmicutes	Negativicutes	Selenomonadales	Veillonellaceae	Dialister		[9]
				Firmicutes	Negativicutes	Acidaminococcales	Acidaminococcaceae	Phascolarctobacterium
				Bacteroidetes	Bacteroidia	Bacteroidales	Bacteroidaceae	Bacteroides
				Bacteroidetes	Bacteroidia	Bacteroidales	Rikenellaceae	Alistipes
				Actinobacteria	Actinobacteria	Bifidobacteriales	Bifidobacteriaceae	Bifidobacterium
				Actinobacteria	Actinobacteria	Coriobacteriales	Coriobacteriaceae	Adlercreutzia
				Proteobacteria	Deltaproteobacteria	Desulfovibrionales	Desulfovibrionaceae	Bilophila
Central system	AD patients	Brain	PCR EM IEM	Chlamydia	Chlamydiae	Chlamydiales	Chlamydiaceae	Chlamydophila	Chlamydia pneumoniae	[40]
			PCR	Proteobacteria	Gammaproteobacteria	Pseudomonadales	Methylobacteriaceae Moraxellaceae Bradyrhizobiaceae Sphingomonadaceae Comamonadaceae Xanthomonadaceae			[13]
			PCR	Bacteroidetes						[13]
			PCR	Chlamydia	Chlamydiae	Chlamydiales	Chlamydiaceae	Chlamydophila	Chlamydia pneumoniae	[41]
			PCR	Spirochetes	Spirochaetes	Spirochaetes	Spirochaetaceae	Borrelia Treponemas	Borrelia burgdorferi T. pectinovorum T. amylovorum T. lecithinolyticum T. maltophilum, T. medium T. socranski	[42]
			PCR	Chlamydia	Chlamydiae	Chlamydiales	Chlamydiaceae	Chlamydophila	Chlamydia pneumoniae	[43]
			EM AFM	Spirochetes						[44]
			PCR	Chlamydia	Chlamydiae	Chlamydiales	Chlamydiaceae	Chlamydophila	Chlamydia pneumoniae	[45]
			IF	Bacteroidetes	Bacteroidia	Bacteroidales	Porphyromonadaceae	Porphyromonas	P. gingivalis	[38]
			IF	Spirochetes	Spirochetes	Spirochete	Spirochetaceae	Treponema	T. denticola T. forsythia	[38]
			WB	Spirochetes	Spirochetes	Spirochetes	Spirochetaceae	Borrelia	Borrelia burgdorferi	[46]
			WB ICC PCR	Proteobacteria	Gammaproteobacteria	Enterobacterales	Enterobacteriaceae	Escherichia coli		[15]
		CSF	PCR	Chlamydia	Chlamydiae	Chlamydiales	Chlamydiaceae	Chlamydophila	Chlamydia pneumoniae	[47]
			ELISA	Proteobacteria	Epsilonproteobacteria	Campylobacterales	Helicobacteraceae	Helicobacter	Helicobacter pylori	[48]
			Serological analysis ELISA WB	Spirochetes	Spirochetes	Spirochetes	Spirochetaceae	Borrelia	Borrelia burgdorferi	[46]
			Histopathologic analysis	Spirochetes						[49]

Open in a new tab

AD Alzheimer’s disease, AFM atomic force microscopy, CSF cerebrospinal fluid, ELISA enzyme-linked immunosorbent assay, EM electron microscopy, ICC immunocytochemistry, IEM immunoelectron microscopy, IF immunofluorescence, IHC immunohistochemistry, PCR polymerase chain reaction, WB western blot

Interestingly, the gram-negative bacteria penetrate the BBB and affect the brain through four potential mechanisms (Fig. 1). First, gram-negative bacteria disrupt the intercellular junctions and induce endothelial cell detachment using their adhesin, pili, and fimbria, allowing them to penetrate the BBB through the paracellular pathway [54]. For instance, the pilus‐mediated signaling events promote alterations in tight junction organization. Escherichia coli (E. coli) binds to brain microvascular endothelial cell receptors to trigger the release of interleukin (IL)-6 and IL-8, and production of inducible nitric oxide synthase (iNOS), and at the meantime breaks down tight junctions between endothelial cells to aggravate BBB disruption [54]. Second, gram-negative bacteria can penetrate the BBB and enter the brain through necrosis of endothelial cells caused by exotoxins, such as hemolysin and protease. Injection of heme carrier protein 1, a component of the Type VI secretion system of E. coli K1, into the cytoplasm of human brain endothelial cells induces necrosis of endothelial cells [55]. Third, gram-negative bacteria internalize into the BBB through transcytosis via interactions between bacterial outer membrane proteins and endothelial cells [55, 56]. The E. coli K1 promotes bacterial transcytosis across the endothelium through outer membrane protein A (OmPA), invasion of the brain endothelium protein (IbeA), endothelial receptors beta-form of the heat-shock gp96 (Ecgp96), and contactin-associated protein 1. The gram-negative bacteria that enter the brain through transcytosis can survive and proliferate by reducing or escaping from the immune response. Finally, the gram-negative bacteria can enter the CNS through the cranial nerves. In particular, the trigeminal and olfactory nerves are suggested as major paths for oral bacteria to enter the brain [57], with several gram-negative oral bacteria capable of affecting the CNS through these neural tracts [58]. Studies using BALB/c mice and the AD model showed that oral bacteria migrate to the brain at a very high frequency through the cranial nerve [59, 60]. Furthermore, it has been reported that DNA of P. gingivalis, which is a gram-negative oral anaerobe involved in the pathogenesis of periodontitis, is characteristically detected in the brains and CSF of patients with AD [59]. In addition, H. pylori, a gram-negative bacterium, can enter the CNS through the oral–nasal–olfactory pathway or the gastrointestinal tract–brain neural pathway [61]. These studies support the hypothesis that the gram-negative bacteria can directly penetrate the brain. In this respect, the gram-negative bacteria penetrating the BBB can affect the onset or progression of AD.

Possible roles of gram-negative bacteria in AD pathogenesis

Microbiota dysbiosis

Under healthy conditions, most intestinal microbiomes interact with the brain through several mechanisms, including neurotransmitter generation, and contribute to the maintenance of brain homeostasis [62]. Increasing evidence suggests that the gastrointestinal tract is the bridge between the microbiota and the CNS [63]. The link between the microbiome and brain disorders emerged from the impact of gastrointestinal microbes on the development of microbial byproducts in the brain [64]. The microbial-derived byproducts are active mediators of gut-brain communication and may be potential therapeutic targets for neurodevelopmental and neurodegenerative disorders. Particularly, bacterial byproducts and exotoxin molecules, such as capsular proteins, flagellin, short-chain fatty acids (SCFA), fimbrillin, peptidoglycan, proteases, gingipain, vacuolating cytotoxin A (VacA), and methylglyoxal (MG), may be considered pathogen-associated molecular patterns. Moreover, exotoxins interact with pattern recognition receptors, such as toll-like receptors (TLR) 2 and 4. Thus, bacteria imbalance and gut exotoxins induce neuroinflammatory reactions, such as microglial cell activation, affecting the function of neuronal cells [65]. The dysregulated microbiota-induced inflammation may also lead to the invasion of microbes or microbial byproducts into the brain, neuroinflammation, and production of Aβ and phosphorylated tau [66]. One study reported that alterations of the composition of gut microbiota in APP/PS1 mice are related to the increased Aβ levels in the brain and impairment of cognitive function. Moreover, another study found that the dysregulation of microbiota, intestinal epithelial barrier dysfunction, and vascular Aβ deposition occur in the intestine before the onset of cerebral Aβ deposition in Tg2576 mice [67]. These reports suggest that microbiota dysregulation is related to the development and progression of AD.

Aβ homeostasis

The precipitate, which shows a β-folded sheet structure located vertical to the fibrous axis and is rich in aggregated insoluble lipoproteins, was designated as amyloid. Because of the hydrophobic nature of the aromatic amino acid peptides that compose the primary sequence of APP-derived amyloid, self-aggregation of amyloid monomers compiles over time into dimers, oligomers, and fibrils. Significant inflammatory reactions and neurodegeneration from amyloid accumulation appear in the brain, which affects neurodegenerative diseases, such as AD, Parkinson's disease, and prion disease [68]. Surprisingly, many studies have revealed the presence of bacteria-produced amyloids [68–70] (Fig. 2). The bacterial amyloids have a biophysical nature that is highly similar to human-derived amyloids, including the aggregate-forming ability [71, 72]. Although the amyloid produced by bacteria differs in its primary structure from the amyloid produced in the CNS, they have similarities in their tertiary structure [73]. Exposure to bacterial amyloid proteins in the gut could provoke systemic inflammation [74]. Moreover, bacterial amyloid affects disease progression by interacting with Aβ present in the AD brain (Table 3). The interaction of bacterial amyloid with neuronal amyloid, which is endogenously produced in the brain, promotes either their aggregation or cross-seeding in the AD brain [75, 76]. Furthermore, bacterial amyloid significantly promotes Aβ pathology in AD [69]. Curli is a well-known gram-negative bacterial amyloid. It is an integral part of the biofilm extracellular matrix produced by certain strains of enterobacteria, such as E. coli [77]. CsgA and CsgB are not only two major structural components of curli fibers, but are also essential components of biofilms [78]. In particular, the structure of the fibril produced by CsgA and CsgB of curli proteins is very similar to that of amyloid [79]. Interestingly, the fibril includes a β-sheet structure similar to Aβ and has been reported to form fibrillar aggregates [80]. The bacterial amyloid from curli may be a potential contributor to Aβ pathology in AD since several amyloid proteins interact with Aβ to induce co-aggregation or cross-seeding [37, 75]. In addition, FapC, a bacterial amyloid from Pseudomonas, is another strong contributor to Aβ pathology [81]. The FapC fibril is a powerful accelerator of Aβ fibrillization in AD [82]. In the co-culture of Aβ and FapC seeds, the rate of increase of the β-sheet ratio was more than three times above the Aβ-only culture [82]. Furthermore, FapC has been reported to promote Aβ-associated pathology several times faster in the AD zebrafish model [82]. Surprisingly, the bacterial amyloid and Aβ can bind to the same receptor due to their structural similarity. For example, similar to Aβ, the bacterial amyloid from curli can bind to the TLR2-TLR1-CD14 (cluster of differentiation 14) complex, which facilitates the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway [83]. Moreover, MG, an intermediate metabolite of glucose metabolism in cells, is widely secreted by gram-negative bacteria such as E. coli, and distributed at a high rate in the body [84]. The MG acts as a ligand for the receptor for advanced glycation end products (RAGE), resulting in increased beta-site amyloid precursor protein cleaving enzyme 1 (BACE-1) expression and Aβ levels [85, 86]. In addition, it has been shown that P. gingivalis increases Aβ production by increasing the gene expression of APP and BACE1 and decreasing the gene expression of disintegrin and metalloproteinase domain-containing protein 10 (ADAM10) [59, 87]. Moreover, gingipain, a family of proteases secreted by P. gingivalis, can affect to activate γ-secretase through cleavage of caspase-3 [87]. In addition, three proteinase genes that contribute to the virulence of P. gingivalis, RgpA, RgpB, and Kgp, have been associated with Aβ production. In particular, RgpB has been reported to induce massive generation of Aβ by activating the metalloproteinase meprin β, which is an alternative BACE1 cleavage of APP [88]. Furthermore, the load of KgpB is particularly increased in the AD brain compared to the healthy brain, and RgpB has been reported to co-localize with Aβ [59]. Collectively, these findings suggest that bacterial molecules from gram-negative bacteria could induce the production and aggregation of Aβ, affecting the onset and progression of AD.

Fig. 2 — The pathological mechanisms underlying the effect of gram-negative bacteria in Alzheimer’s disease. The gram-negative bacteria produce a variety of exotoxins, such as gingipain, methylglyoxal (MG), bacterial amyloid, vacuolating cytotoxin (VacA), bacterial amino-acid, heme carrier protein (Hcp1), matrix metalloproteinase-8 (MMP8), phosphorylcholine, short-chain fatty acid (SCFA), and tryptophan. The gram-negative bacteria and exotoxins can penetrate the BBB and affect the AD-related pathology. Concerning Aβ aggregation, MG and gingipain are involved in the increase of Aβ production; bacterial amyloid and gram-negative bacteria can induce Aβ aggregation. Concerning hyperphosphorylated tau and neurofibrillary tangles, gingipain, MG, and gram-negative bacteria can provoke the hyperphosphorylation of tau; gingipain and gram-negative bacteria can also promote the aggregation of phosphorylated tau. Concerning neuroinflammation, the Aβ-induced activation of microglia and astrocytes contributes to a neuroinflammatory response, affecting neurodegeneration. The gram-negative bacteria and gingipain can increase the release of inflammatory cytokines. Concerning neurodegeneration, gingipain, MG, and gram-negative bacteria can induce neuronal death. The gram-negative bacteria provoke neuronal loss through the activation of the neuronal TLR4 signaling pathway. Hcp1: Heme carrier protein; IL-6: Interleukin 6; IL-1β: Interleukin 1β; IL-18: Interleukin 18; MMP8: Matrix metalloproteinase-8; NLRP1: Nod-like receptor protein 1; RAGE: Receptor for advanced glycation end products; SCFA: Short-chain fatty acid; TNF-α: Tumor necrosis factor α; VacA: Vacuolating cytotoxin A

Table 3.

Gram-negative bacteria-derived products affect Alzheimer’s disease and other diseases

	Gram-negative bacteria-derived products	AD-related pathology					References
	Gram-negative bacteria-derived products	Aβ	Tau	Neuroinflammation	Cell death	BBB disruption	References
In Alzheimer’s disease	Gingipain	Production ↑	Hyperphosphorylation ↑ Aggregation ↑	Proinflammatory cytokines ↑	Pyroptosis ↑ Caspase-1 ↑		[59]
	Methylglyoxal (MG)	Production ↑	Hyperphosphorylation ↑		Oxidative stress↑ Apoptosis↑		[64, 85, 89]
	Hcp1					Endothelial cell disruption ↑	[55]
	Bacterial amyloid	Aggregation ↑					[82]
In other diseases	VacA			Proinflammatory cytokines ↑	Cell vacuolation ↑		[90, 91]
	Bacterial amino-acid			Systemic inflammation ↑			[10]
	Hcp1					Endothelial cell disruption ↑	[55]
	MMP8					Junctional protein degradation ↑	[92]
	Phosphorylcholine			Proinflammatory cytokine ↑			[93]
	Short chain fatty acid			Proinflammatory cytokine ↑ Gliosis ↑		Endothelial cell disruption ↑	[94–96]
	Tryptophan			Proinflammatory cytokine ↑ Gliosis ↑		Endothelial cell disruption ↑	[97]

Open in a new tab

AD Alzheimer’s disease, Aβ Amyloid-β, BBB blood–brain barrier, Hcp1 Heme carrier protein 1, MMP8 matrix meralloproteinase-8, ROS reactive oxygen species, VacA vacuolating cytotoxin

Tau pathology

Hyperphosphorylated tau aggregation is the main pathological hallmark of AD [98]. Neurofibrillary tangles (NFTs) consist of hyperphosphorylated and aggregated microtubule-associated protein tau [99], while the intermediate form of tau causes cytotoxicity and cognitive impairment [100]. Tau hyperphosphorylation is regulated by various kinases that are affected by numerous factors, including gram-negative bacteria [101, 102] (Fig. 2). Helicobacter pylori induces tau hyperphosphorylation by activating the glycogen synthase kinase-3β (GSK-3β) [102]. Moreover, it has been revealed that P. gingivalis can increase tau hyperphosphorylation at, e.g., Thr231 and Ser396 residues, in human iPSC-differentiated neuronal cells and C57BL/6 mice [87, 103]. Particularly, P. gingivalis infection activates GSK-3β [104]. Furthermore, gingipain can contribute to tau hyperphosphorylation by regulating the protein kinase B (Akt)/GSK-3β activity by cleaving procaspase-3 to caspase-3 [59, 105]. Gingipain is involved in tau fragmentation and generation of paired helical filament through tau proteolysis; the tau fragments can induce tau aggregation and phosphorylation [106–108] (Table 3). Interestingly, Kgp has been reported as a trigger or accelerator of tau pathology [59]. The hexapeptide motif-containing tau peptide generated by Kgp can be easily hyperphosphorylated and contribute to the formation of paired helical filaments and NFT. Similarly, MG has been reported to induce tau hyperphosphorylation through the GSK-3β activity [89]. Furthermore, DNA derived from several species of gram-negative bacteria, such as E. coli and P. gingivalis, has been reported to promote tau pathology [109]. In particular, the gram-negative bacterial DNA—frequently reported in patients with AD—strongly induces tau misfolding and aggregation [109]. Therefore, gram-negative bacteria could initiate or exacerbate tau pathology by inducing tau hyperphosphorylation and aggregation in AD.

Neuroinflammation

Neuroinflammation is a pathological hallmark induced by abnormally aggregated Aβ peptides in AD [110, 111]. Moreover, microglia activated by Aβ can accelerate neurodegeneration in the brain during AD [111]. Gram-negative bacteria are known triggering factors for inflammatory responses [112]. A study confirmed that the effect of microbiota on microglial maturation in germ-free mice could be regulated by SCFA, a byproduct of bacterial metabolism [94]. Furthermore, the microbial metabolites of tryptophan can modulate astrocyte activity [97]. These results show that the bacterial-derived byproducts, such as VacA, SCFA, phosphorylcholine, and tryptophan [90, 94–97], are involved in neuroinflammation by modulating microglia and astrocyte activity. Although this evidence demonstrates the pivotal role of byproducts from gram-negative bacteria in neuroinflammation, only a few studies have investigated their effects in AD. A recent study showed that the P. gingivalis oral infection causes strong microglial activation in the brains of apolipotein E (ApoE)^−/− mice [60]. In particular, gingipain from P. gingivalis can lead to the release of neuroinflammatory cytokines in an AD brain [59] (Fig. 2). In addition, respiratory infection of Bordetella pertussis in APP/PS1 mice increases brain infiltration of T cells and activation of microglia and macrophages [113]. Helicobacter pylori infection stimulates the secretion of pro-inflammatory cytokines, such as tumor necrosis factor-α (TNF-α) and IL-6, causing inflammation-related neurodegeneration [61]. Moreover, it has been reported that monocytes infected with Chlamydia pneumoniae (C. pneumoniae) may contribute to late-onset AD by inducing secretion of pro-inflammatory cytokines and chemokines from microglia and astrocytes [114]. Furthermore, the C. pneumoniae-infected microglia show increased levels of TNF-α [115], a critical neuroinflammatory factor in AD. These findings imply that the gram-negative bacteria introduced into the CNS can aggravate AD pathology through strong neuroinflammation.

Neuronal cell death

Neuronal loss is a prominent pathological feature of AD [3]. Surprisingly, gram-negative bacteria, H. pylori, can induce neuronal cell death by secreting VacA [91]. Moreover, MG from gram-negative bacteria—a cell death-related toxin—has been reported to induce oxidative stress and apoptosis through activation of nicotinamide adenine dinucleotide phosphate oxidase and production of reactive oxygen species [64]. In AD, MG is a potential key factor that triggers neuronal death through the decrease of mitochondrial membrane potential, down-regulation of Bcl-2, and up-regulation of pro-apoptotic proteins, such as caspase-3 and Bax [116, 117]. These mitochondrial dysfunctions caused by MG can accelerate AD neurodegeneration. TLR4 activates the nod-like receptor protein 3 by recognizing gram-negative bacteria; it is a key receptor for the onset of neurodegenerative diseases, including AD [118]. Therefore, activation of TLR4 signaling by gram-negative bacteria can lead to neuronal cell death [119]. Importantly, gram-negative bacteria can trigger neuronal cell death through not only their byproducts but also the bacteria themselves (Fig. 2). Taken together, both gram-negative bacteria and their byproducts could play a key role in neuronal cell death and neurodegeneration in AD.

Specific roles of LPS from gram-negative bacteria in AD

Peripheral and central localization of LPS in AD

Most LPS is produced by intestinal gram-negative bacteria; subsequently, it can escape the intestine and enter the circulatory system [120]. The high concentration of LPS can induce TLR4-dependent CD14 upregulation in enterocytes, thereby damaging the intestinal epithelial barrier and increasing the gut permeability. Surprisingly, one study reported that the LPS level in the plasma is increased 3–6 times in AD patients (61 ± 42 pg/ml) compared to that in healthy controls (21 ± 6 pg/ml) [22]. Such changes could be associated with an increased permeability induced by LPS in the intestine [121, 122]. This suggests that, as AD increases, the intestinal epithelial barrier may have an increased permeability to intestinal LPS, which leads to the spread of LPS throughout the body.

Surprisingly, several previous studies have shown an extensive and characteristic distribution of LPS in the AD brain (Table 4). LPS localization has been reported in various regions, such as the lateral ventricle of the parietal lobe and neocortex of the temporal lobe of the AD brain, suggesting that it can be widely distributed in AD brains [38, 123–125]. The mechanisms by which LPS crosses the BBB have not yet been clearly elucidated; however, several mechanisms have been proposed. First, LPS binds to the lipopolysaccharide-binding proteins (LBP) and can pass the BBB using receptors distributed within the BBB, such as scavenger receptor class B type I, apolipoprotein A-I and ApoE, and apolipoprotein E receptor 2 (ApoER2) [126] (Fig. 3). Second, LPS can be transported through phagocytosis by peripheral immune cells. In particular, LPS stimulation increases both the secretion of peripheral and central inflammatory cytokines and the expression of adhesion molecules in BBB endothelial cells, such as p-selectin, intercellular adhesion molecules-1, and vascular cell adhesion molecules-1, which potentially increases immune cell entry into the BBB [127–130]. Third, it has been suggested that high LPS doses induce a pro-inflammatory response, destroying the BBB and allowing LPS to enter the CNS [131]. For instance, either LPS or LPS-induced TNF-α can degrade glycocalyx in the endothelial cells of the BBB, thereby increasing the BBB permeability [132]. Fourth, LPS entry into the BBB could occur without mediation, by binding to the CD14/TLR4 complex on BBB endothelial cells [126]. Fifth, another interesting possibility is that the LPS molecules not only pass directly through the BBB [133] but also enter the brain through gram-negative bacteria [134], which are capable of transferring both exotoxins and endotoxins to the host cells through outer membrane vesicles (OMVs) [135]. An OMV is a bacterial transporter capable of entering various cell types, such as gut and BBB endothelial cells. Therefore, LPS can be introduced into neuronal cells through the OMV-containing LPS, derived from gram-negative bacteria. It is well established that the OMV-delivered LPS induces a stronger physiological response than pure LPS [135]. Therefore, LPS transmitted through gram-negative bacteria in the brain, can be more harmful to neuronal cells. Moreover, it is possible that LPS can accumulate in neuronal cells [124]. Taken together, LPS could sufficiently contribute to AD pathology through various BBB penetration mechanisms.

Table 4.

Localization and change of lipopolysaccharides in Alzheimer’s disease

Source	Subject	Method	Main findings	References
Brain	AD patients	Immunoblot	LPS was detected in the area adjacent to the lateral ventricle of the parietal lobe of AD brain	[38]
	AD patients	WB IHC	LPS was detected in temporal lobe neocortex perinuclear region of AD brain LPS was co-localized with Aβ plaque	[125]
	AD patients	IF WB	LPS was detected in superior temporal gyrus gray matter, frontal lobe white matter, and periventricular white matter of AD brain LPS was localized with Aβ plaque, neurons, microglia, and oligodendrocytes	[15]
	AD patients	IHC	LPS was detected in superior temporal lobe neocortex of AD brain LPS was localized in neurons	[124]
	AD patients	WB	LPS was detected in temporal lobe neocortex and hippocampus of AD brain	[123]
	5×FAD mice	IF	LPS was detected in pyramidal and stratum oriens regions of hippocampus of AD brain LPS was co-localized with LPS-phagocytic cell	[23]
Blood	AD patients	LAL assay	LPS levels in AD patients were 3- to 6-fold compared with that in control	[22]
	5×FAD mice	ELISA	LPS levels in AD mice were 4-fold compared with that in control	[23]
	5×FAD mice	LAL assay	LPS levels in AD mice were 4-fold compared with that in control	[136]
Feces	5×FAD mice	LAL assay	LPS levels in AD mice were 3- to 4-fold compared with that in control	[23, 136]

Open in a new tab

AD Alzheimer’s disease, ELISA Enzyme-linked immunosorbent assay, IF immunofluorescence, IHC immunohistochemistry, LAL assay limulus amebocyte lysate assay, LPS lipopolysaccharides, WB western blot

Fig. 3 — Mechanisms of lipopolysaccharide (LPS) penetration to the central nervous system. LPS produced in the peripheral system penetrates the BBB and enters the brain. ① LBP is a soluble acute-phase protein that binds to bacterial LPS to elicit immune responses. LBP facilitates LPS penetration of the BBB through various receptors, such as Scavenger reception class B type 1 (SR-B1) and apolipoprotein E receptor 2 (ApoER2). ② LPS is transported to BBB by peripheral immune cells. ③ LPS enters the brain via damaged BBB caused by high concentrations of LPS and LPS-induced pro-inflammatory cytokines. ④ LPS is directly recognized by the cell surface pattern recognition receptor CD14/TLR 14 complex, resulting in penetration to the BBB. ⑤ LPS is transported into the brain through gram-negative bacteria transporters, such as OMV. CD14: Cluster of differentiation 14; CNS: Central nervous system; LBP: Lipopolysaccharide-binding protein; OMV: Outer membrane vesicle; PNS: Peripheral nervous system; TLR4: Toll-like receptor 4; VCAM1: Vascular cell adhesion molecules-1

Pathogenic contribution of LPS to AD-related pathology

Aβ homeostasis

Aβ accumulation is significantly reduced in sterile APP mice, but consistently increased in LPS-treated APP mice [32, 137], highlighting the role of LPS, apart from established AD pathogenic factors, and presenting LPS as a potential risk factor, equally strong as AD’s genetic components. LPS modulates Aβ production by significantly increasing the activity of APP-cleaving enzymes, such as BACE-1 and γ-secretase, while decreasing α-secretase activity [138] (Fig. 4). Moreover, LPS increases mRNA expression of APP and contributes to the production of Aβ in the hippocampus through the cathepsin B-related mechanism [139]. In LPS-injected rodents, BACE1 immunoreactivity and Aβ accumulation were found in the ipsilateral cerebral cortex and hippocampal formations [140]. Moreover, LPS increases Aβ oligomers by promoting Aβ aggregation [18, 141]. Furthermore, the LPS-induced systemic inflammation could provoke Aβ clearance impairment via (1) down-regulated expression of low-density lipoprotein receptor-related protein 1 (LRP-1); (2) inhibition of Aβ entry into the blood vessels in the brain; and (3) dysfunction of p-glycoprotein [142]. These studies demonstrate that the LPS-induced Aβ burden and Aβ plaques could play key roles in Aβ-related AD pathology.

Tau pathology

LPS is potentially instrumental in exacerbation of tau pathology (Fig. 4). First, LPS induces tau phosphorylation through not only hypoactivation of tau phosphatase but also activation of cyclin-dependent kinase 5 (CDK-5) and GSK-3β [143, 144]. LPS may stimulate the activation of GSK-3β through regulating the phosphoinositide-3-kinase (PI3K)/Akt pathway, increasing the production of phosphorylated tau [104, 145]. In particular, LPS can increase phosphorylation of tau in the hippocampus [144, 146, 147]. Second, LPS induces tau aggregation in the AD brain [143]. Several studies have reported that LPS contributes to the tau aggregation through activation of CDK-5 and GSK-3β in the 3xTg model [143, 144]. Accumulating evidence suggests that LPS accelerates tau pathology by acting as an exogenous regulator of kinases such as mitogen-activated protein kinase (MAPK), GSK-3β, c-Jun N-terminal kinases, and p38 [143, 148]. These results suggest that LPS may affect tau pathology by inducing hyperphosphorylation and aggregation of tau. Moreover, LPS could play a key role in tau hyperphosphorylation and aggregation, which is considered a major factor and therapeutic target for AD pathology.

Neuroinflammation

Accumulating evidence suggests that LPS contributes to AD pathology through glial activation modulation (Fig. 4). It has been reported that LPS administration increases microglial density in the brain [141]. In particular, LPS is an agonist of glial TLR4, activating the myeloid differentiation primary response 88/toll/interleukin-1 receptor-domain-containing adapter-inducing interferon-β (MyD88/TRIF) pathway and promoting pro-inflammatory responses by activating NF-κB [149–151]. In contrast, some studies have suggested that LPS promotes the anti-inflammatory response [152, 153]. It has been proposed that continuous mild LPS exposure reduces inflammatory responses in the brain by suppressing pro-inflammatory mediators and boosting anti-inflammatory mediators [152]. In addition, several studies have revealed that low-dose LPS can induce anti-inflammatory responses in AD animal models [154–156]. The possible underlying mechanism is that the low-dose LPS exposure reduces inflammation via upregulating the expression of MyD88-dependent signaling pathway inhibitors like IRAK-M, Ship, and Tollip [157]. Unfortunately, the precise mechanism by which mild LPS exposure provokes the anti-inflammatory response is not known. Although the role of LPS-exposed microglia in the AD brain is not clear, accumulating evidence suggests that LPS may exacerbate AD pathology through interactions with several receptors related to neuroinflammation [158, 159]. Notably, LPS significantly increases the expression level of RAGE [160], a receptor critically involved in AD pathology such as Aβ production and clearance, tau pathology, and synaptic degeneration [161]. In particular, the microglial RAGE-dependent signaling pathway plays a causative role in neuroinflammation, Aβ deposition, and cognitive impairment in AD [162]. Interestingly, it has been reported that stimulation of RAGE by LPS increases endothelial permeability and activates NF-κB [163]. The glial NF-κB activation by LPS leads to secretion of pro-inflammatory cytokines. In addition, recent studies have suggested that LPS can induce leukocyte infiltration into the brain and microglial activation by increasing the generation of reactive oxygen species through NADPH oxidase 2 (NOX2) activation [164]. The widespread high-level LPS in the AD brain alone can cause pathological and excessive neuroinflammatory reactions. Interestingly, LPS is also a ligand for triggering receptors expressed on myeloid cells 2 (TREM2), a receptor that regulates microglial phenotype switching [165]. Stimulation of TREM2 by LPS can convert the microglial phenotype from an anti-inflammatory phenotype to a pro-inflammatory phenotype [166]. Particularly, not only Aβ-induced neuroinflammation but also LPS-induced neuroinflammation could facilitate neurodegeneration and cognitive impairment [167]. These results suggest that the LPS-induced neuroinflammation could act as a direct and fatal factor in AD pathology and cognitive dysfunction.

Neurodegeneration

LPS induces synaptic loss within the CNS [168] and reduces synaptic plasticity in the brain [169]. Moreover, LPS affects the inhibitory and excitatory synapses of adult-born hippocampal neurons, induces neuronal and synaptic loss, and reduces cognitive function [170, 171], supporting the hypothesis that LPS in AD is involved in neurodegeneration (Fig. 4). In addition, LPS can inhibit neuronal function via damage to myelin in AD [172]. It has been reported that LPS causes damage to oligodendrocytes and increases myelin basic protein degradation in the AD brain. The first mechanism for LPS-induced neurodegeneration is that LPS induces the activated p38α MAPK signaling pathway in microglia and increases TNF-α secretion [173, 174]. In addition, LPS is one of the potent factors capable of activating NOX2 in the CNS [164, 175]. The NOX2 activation in glia and neurons can induce neuronal cell death through massive oxidative stress, which has been suggested as a contributor to several neurodegenerative diseases, including AD [176, 177]. The LPS-induced neuroinflammation such as NOX2 activation can be a possible additional contributor to neurodegeneration in AD pathology. Second, LPS facilitates neurodegeneration through mitochondrial dysfunction [178]; namely, LPS may affect mitochondrial fusion genes, such as mitofusin (Mfn)1, Mfn2, and OPA1, which are important in neurodegenerative diseases, including AD. In addition, LPS leads to neurodegeneration by inducing oxidative stress and triggering the mitochondrial apoptotic pathway [179]. Third, LPS can directly induce neuronal cell death through neuronal TLR4, which is a major receptor that plays a key role in the activation of the inflammatory response on AD. LPS not only increases TLR4 expression but also acts as a ligand for neuronal TLR4, inducing the transcription of caspase-11 and promoting the activation of the inflammasome [180, 181]. Since TLR4 expression is also increased by aging and Aβ, the interaction between LPS and TLR4 may be more fatal to AD [182]. NF-κB, a well-known downstream molecule of the TLR4/Myd88/TRIF signaling pathway, is also known to be important for neuronal survival and acts either as a pro-apoptotic or anti-apoptotic factor [183]. Consequently, LPS can cause neuronal death by directly acting on neurons, such as acting on neuronal receptors followed by influx into neuronal cells through OMV [181]. Taken together, these studies demonstrate that LPS can induce neurodegeneration and affect the initiation and progression of AD.

Gram-negative bacteria and their LPS as therapeutic targets in AD

The paradigm of AD treatment research is transforming from identifying a single target towards a multi-target therapy for various pathogenic factors. Interestingly, several therapeutic approaches targeting LPS-releasing gram-negative bacteria and microbiota have been proposed.

Antibiotics for AD treatment

Consistent with the influence of gram-negative bacteria on AD pathology, antibiotics have been demonstrated to reduce pathological changes in AD animal models and improve symptoms in AD patients (Table 5). Accumulating evidence on antibiotic therapy for AD suggests that the decrease of gram-negative bacteria involved in AD-related pathology by antibiotics is beneficial in the treatment of AD. However, some studies have suggested potential risk of side effects associated with their long-term use [184]. One of the largest risk factors is the antibiotic-induced microbiome imbalance [185]. In particular, a broad range of antibiotics can affect both gram-positive and gram-negative bacteria, resulting in imbalanced gut microbiota homeostasis [186]. This possibility should be fully considered in the development of AD antibiotic therapies. Unfortunately, there are no specific antibiotics for gram-negative bacteria in clinical trials for AD treatment. As the LPS from gram-negative bacteria has a remarkable adverse effect on AD, it would be important to develop a drug that not only targets gram-negative bacteria but also neutralizes the secreted/remaining endotoxin. Consequently, to minimize the side effects of existing broad-spectrum antibiotics, multispecific-target antibiotics, which target AD-specific gram-negative bacteria and their LPS, must be used.

Table 5.

Therapeutic approaches for Alzheimer’s disease: focusing on microbiota and gram-negative bacteria-derived molecules

Therapeutic methods	Treatment or drug	Subject or model	Target (or antibiotic range)	Effects or trial phase	References
Antibiotics	Doxycycline	APP/PS1 mice	Gram-positive bacteria Gram-negative bacteria	Cognitive dysfunction↓ Neuroinflammation↓	[187]
	Gentamicin, Vancomycin, Metronidazole, Neomycin, Ampicillin, Kanamycin, Colistin, and Cefaperazone	APP/PS1 mice	Gram-positive bacteria Gram-negative bacteria	Aβ deposition↓ Soluble Aβ↓ Neuronal loss↓ Gliosis↓	[188]
	Rifampicin	AD patients	Gram-positive bacteria Gram-negative bacteria	Phase 2	NCT03856359
	Doxycycline Rifampicin	AD patients	Gram-positive bacteria Gram-negative bacteria	Phase 3	NCT00439166
	Doxycycline Rifampicin	AD patients	Gram-positive bacteria Gram-negative bacteria	Phase 3	NCT00715858
	Minocycline	AD patients	Gram-positive bacteria Gram-negative bacteria	Phase 2	NCT01463384
	Doxycycline Rifampicin	AD patients	Gram-positive bacteria Gram-negative bacteria	Dysfunctional behavior↓ Cognitive dysfunction↓	[189]
Gingipain inhibitor	COR271 COR286 COR388	BALB/c mice	Gingipain	Aβ deposition↓ TNF-α↓ Neuronal loss↓	[59]
Gingipain inhibitor	COR388	AD patients	Gingipain	Phase 2/3	NCT03823404
Probiotics	Lactobacillus acidophilus Bifidobacterium bifidum Bifidobacterium longum	Aβ-administered rats	Intestinal microbiota	Cognitive dysfunction↓ LTP↑	[190]
	Bifidobacterium longum Lactobacillus acidophilus	APP/PS1 mice	Intestinal microbiota	Cognitive dysfunction↓ Aβ deposition↓	[191]
	Lactobacillus plantarum MTCC1325	D-galactose-induced AD albino rats	Intestinal microbiota	Aβ deposition↓ NFT↓ Cognitive dysfunction↓ Acetylcholine level↑	[192]
	Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum, Lactobacillus fermentum	AD patients	Intestinal microbiota	MMSE score↑	[193]
	Lactobacillus casei W56, Lactococcus lactis W19, Lactobacillus acidophilus W22, Bifidobacterium lactis W52, Lactobacillus paracasei W20, Lactobacillus plantarum W62, Bifidobacterium lactis W51, Bifidobacterium bifidum W23, Lactobacillus salivarius W24	AD patients	Intestinal microbiota	Systemic inflammation↓	[194]
	Lactobacillus acidophilus, Bifidobacterium bifidum, Bifidobacterium longum	AD patients	Intestinal microbiota	MMSE score↑	[195]
	Lactobacillus fermentum, Lactobacillus plantarum, Bifidobacterium lactis Lactobacillus acidophilus, Bifidobacterium bifidum, Bifidobacterium longum	AD patients	Intestinal microbiota	Cognitive dysfunction-	[196]
Intestinal microbiota reconstruction	Mediterranean-style diet	MCI patients	Non-specific bacteria	Changes of the microbiota	[157]
	Mediterranean-style diet	MCI patients	Non-specific bacteria	Changes of the microbiota	[197]
	Curcumin	APP/PS1 mice	Non-specific bacteria	Cognitive impairment↓ Aβ deposition↓ Changes of the microbiota	[198]
	Folate and vitamin B-12	Aβ-administered rats	Non-specific bacteria	Changes of the microbiota	[199]
	Ginsenoside Rg1	Tree shrew model of AD	Non-specific bacteria	Aβ deposition↓ Phosphorylated tau↓ Pro-apoptotic factor↓ Changes of the microbiota	[200]
	Streptococcus thermophilus, Bifidobacteria longum, Bifidobacteria breve, Bifidobacteria infantis, Lactobacillus acidophilus, Lactobacillus plantarum,Lactobacillus paracasei, Lactobacillus delbrueckii subsp, Bulgaricus, Lactobacillus brevis	3xTg mice	Intestinal microbiota	Cognitive impairment↓ Aβ deposition↓ Neuronal loss↓	[201]
	NK46 (Bifidobacterium longum) oral administration	5xFAD mice	Gram-negative bacteria	Pro-inflammatory cytokines↓ LPS↓ Gliosis↓ Neuronal loss↓ Aβ↓ Cognitive dysfunction↓	[23]
	Fecal microbiota transplant	ADLP^APT mice	Microbiota dysbiosis	Aβ deposition↓ NFT↓ Neuroinflammation↓ Cognitive dysfunction↓	[202]
	Fecal microbiota transplant	AD patients	Microbiota dysbiosis	MMSE score↑	[203]
	Fecal microbiota transplant	AD patients	Microbiota dysbiosis	Phase 1	NCT03998423

Open in a new tab

Ach Acetylcholine, AD Alzheimer’s disease, Aβ Amyloid-β, LPS lipopolysaccharides, LTP long-term potentiation, MCI mild cognitive impairment, MMSE mini-mental state examination, NFT neurofibrillary tangles, NF-kB nuclear factor-κB, SADAScog standardized Alzheimer’s disease assessment scale cognitive subscale

Gingipain inhibitor for AD treatment

P. gingivalis is a typical gram-negative bacterium that exerts a broad and powerful effect on AD pathogenesis [104]. Gingipain, one of the byproducts of P. gingivalis, is a novel therapeutic target for AD treatment, which is associated with AD-related pathologies, such as Aβ and tau pathology, neuroinflammation, and neurodegeneration (Table 3). Indeed, the use of selective inhibitors for gingipain can significantly reduce AD pathology [204]. For instance, COR388, a gingipain inhibitor, is currently under a phase 3 clinical trial (NCT03823404) (Table 5). Taken together, the bacterial exotoxin-specific drugs, such as gingipain inhibitors, can be an attractive therapeutic strategy, as they can simultaneously reduce and inhibit AD-related bacteria and bacterial exotoxin, respectively.

Probiotics for AD treatment

Probiotics have beneficial effects including immune system modulation, synthesis and release of neurotransmitters, protection from physiological stress, host gene expression modulation, pathogen antagonism, and improvement of intestinal epithelial barrier function [205]. Moreover, the hippocampal expression of N-methyl-D-aspartic acid receptor, which is very important in AD pathology, is regulated by gut microbiota [206]. Several studies have suggested the potential therapeutic effect of probiotics in AD (Table 5). Surprisingly, many studies demonstrated that the probiotic treatment in rodent models of AD can reduce Aβ plaques and NFT [191, 192], alleviate neurodegeneration [190, 207], and restore the reduced acetylcholine level [192]. Furthermore, probiotics restore cognitive dysfunction in AD rodent models [190–192]. Evidence for the improvement of AD-related pathology by probiotics has been reported both in AD animal models and in patients. A clinical trial conducted in patients with AD has reported that a 12-week probiotic administration significantly improves the cognitive function in AD patients [193, 195]. The probiotic administration to AD patients has also been reported to alleviate systemic inflammation by reducing intestinal inflammation [194]. The effects of probiotics both in AD animal models and patients might occur through direct probiotic bacterial interaction with AD pathology and the correction of AD-induced microbial dysbiosis. Disruption of microbiota homeostasis, which is maintained through competition between bacterial species, could lead to pathological conditions. Attempts to rebuild the gut microbiota through dietary modulation and intake of food components are receiving attention in the treatment of AD. Modulating the microbiota bias is an important factor in the treatment of many diseases. Considering the changes in gram-negative bacteria in AD (Table 1), the mechanisms of action of probiotics on AD may also include a probiotic antagonistic action against the dysbiosis of gram-negative bacteria.

Intestinal microbiota reconstruction for AD treatment

Microbiota dysbiosis is an important factor in AD-related pathogenesis and progression [208], and several attempts have been made to improve microbiota dysbiosis and the alteration of gram-negative bacteria in AD (Table 5). First, attempts to induce the rebuilding of the gut microbiota through intake of the diet and food components are receiving attention for the treatment of AD [209]. For instance, a Mediterranean-style diet, which emphasizes plant-based foods such as vegetables, beans, whole grain, fruits, nuts and seeds, and plant-based oils [210], was reported to modulate the gut microbiota affecting AD pathology [197, 211]. One study demonstrated that the gut microbiota distribution alters in MCI patients on a Mediterranean diet, particularly decreasing the abundance of gram-negative bacteria Enterobacteriaceae, Akkermansia, Christensenllaceae, and Erysipelotriaceae [211]. Moreover, curcumin can improve AD pathology by regulating the proportion of gram-negative bacteria such as Bacteroidaceae, Rikenellaceae, and Prevotellaceae in AD transgenic mice [198]. Similarly, supplementation of omega-3 fatty acid and DHA alleviates microbiota dysbiosis and reduces AD-related gram-negative bacteria, such as Bacteroidetes, in healthy individuals [212, 213]. Vitamins are closely correlated with microbiota, and intake of folate and vitamin B-12 has been reported to be important for intestinal microbiota homeostasis in a rodent AD model [199, 209]. Moreover, traditional herbal medicine can induce changes in the microbiota in AD. The Ginsenoside Rg1, a traditional herbal medicine, can affect the microbiota of the large intestine by significantly reducing the abundance of gram-negative bacteria, Bacteroidetes, in the tree shrew model of AD [200]. Second, microbiota or fecal transplantation, which involves transplantation of microbiota in the feces of healthy humans into patients to balance the intestinal microflora, is an emerging therapeutic method for AD treatment [203]. Microbiota modulation both reduces cognitive impairment and Aβ aggregates, and restores the impaired neuronal proteolytic pathways in 3xTg mice [214]. Moreover, recent studies have reported therapeutic effects of microbiota transplantation, including reduction of Aβ deposition and NFT, alleviation of neuroinflammation, and amelioration of cognitive decline in ADLP^APT mice [215]; and alleviation of behavioral and psychological symptoms of dementia and continuous improvement of cognitive function in elderly patients with AD who received fecal transplants [216]. However, the safety of fecal transplantation remains controversial. Recently, a patient who underwent fecal transplantation died from E. coli infection, a gram-negative bacterium that secrete “extended-spectrum beta-lactamase” [217]. This suggests that the transplantation of microbiota—including gram-negative bacteria—is an unstable AD treatment. Despite the controversy on stability and side effects, the reconstruction of microbiota distribution through fecal transplantation has relieved the AD-related pathology in both animals and patients with AD. These results suggest that the microbiota, including gram-negative bacteria, may not only be an upstream etiology of AD onset and progression, but also a therapeutic target for AD treatment.

Conclusions

The gram-negative bacteria and their LPS are detected in the CNS as well as in the periphery, and can trigger or accelerate AD pathology. We discuss the alterations and species of gram-negative bacteria in AD (Tables 1 and 2). The gram-negative bacteria can directly penetrate the CNS through various mechanisms (Fig. 1) and influence AD pathogenesis (Fig. 2). Moreover, several gram-negative bacteria are involved in microbiota dysbiosis, Aβ pathology, tau hyperphosphorylation, neuroinflammation, and neurodegeneration in AD. Furthermore, the impact of gram-negative bacterial byproducts on major AD pathologies suggests that the gram-negative bacteria are an essential therapeutic target for AD (Table 3). Importantly, gram-negative bacteria-derived LPS, which is present at high concentrations in AD patients, is a direct pathogenic factor (Fig. 4). The AD pathology-related localization of LPS within the CNS suggests that LPS has unique pathological roles in AD (Table 4). Moreover, LPS is directly involved in AD pathology, including neuroinflammation through microglial TLR4 and induction of neuronal cell death through neuronal TLR4. The ‘LPS cascade phenomenon’, which acts as an upstream molecule triggering AD pathogenesis or accelerating progression by engagement in various aspects of AD pathology, should be considered as a potential therapeutic target for AD treatment. As a novel therapeutic strategy for AD, the modulation of LPS-releasing gram-negative bacteria is receiving much attention (Table 5). Although the bacteria-targeting treatments, such as antibiotics and fecal microbiota transplantation, show potential for AD treatment, there are still concerns regarding their side effects and safety. In particular, potential side effects of the use of non-specific drugs that target bacteria indiscriminately should receive cautions. Therefore, it is important to categorize and characterize gram-negative bacteria that affect AD. Taken together, the gram-negative bacteria and their LPS are not only an upstream pathologic process which influences Aβ and tau pathology, but are also attractive targets for AD treatment. With no practical treatment for AD yet in development, the control of gram-negative bacteria and their LPS may be an excellent strategy to prevent the onset and progression of AD.

Supplementary Information

40035_2021_273_MOESM1_ESM.pptx^{(47.8KB, pptx)}

Additional file 1: Figure S1. Flow diagram showing the study selection process. Flowchart summarizing study selection and inclusion processes in this narrative review, including the example of keywords that were reviewed.

Acknowledgements

Not applicable.

Abbreviations

AD: Alzheimer’s disease
ADAM10: A disintegrin and metalloproteinase domain-containing protein 10
Akt: Protein kinase B
ApoE: Apolipotein E
apoER2: Apolipoprotein E receptor 2
APP/PS1: Amyloid precursor protein/presenilin 1
Aβ: Amyloid beta
BACE-1: Beta-site amyloid precursor protein cleaving enzyme 1
BBB: Blood–brain barrier
C. pneumoniae: Chlamydia pneumoniae
CD14: Cluster of differentiation 14
CDK-5: Cyclin-dependent kinase 5
CNS: Central nervous system
CSF: Cerebrospinal fluid
E. coli: Escherichia coli
Ecgp96: Endothelial receptors beta-form of the heat-shock gp96
GSk-3β: Glycogen synthase kinase-3β
H. pylori: Helicobacter pylori
IbeA: Invasion of the brain endothelium protein A
IL: Interleukin
iNOS: Inducible nitric oxide synthase
LBP: Lipopolysaccharide binding protein
LPS: Lipopolysaccharide
LRP-1: Lipoprotein receptor-related protein 1
MAPK: Mitogen-activated protein kinase
MG: Methylglyoxal
MyD88/TRIF: Myeloid differentiation primary response 88/toll/interleukin-1 receptor-domain-containing adapter-inducing interferon-β
NFT: Neurofibrillary tangles
NF-κB: Nuclear factor kappa-light-chain-enhancer of activated B
OmPA: Outer membrane protein A
OMV: Outer membrane vesicle
P. gingivalis: Porphyromonas gingivalis
PI3K: Phosphoinositide-3-kinase
RAGE: Receptor for advanced glycation end products
SCFA: Short-chain fatty acids
TLR: Toll-like receptor
TREM2: Triggering receptor expressed on myeloid cells 2
VacA: Vacuolating cytotoxin A

Authors' contributions

YN, S-MK, CWK and KWL and IDJ performed the literature search. HSK, SK, SJS and YHP created tables and figures. HSK, SK, SJS, YHP, MM, Y-MP and HDY contributed to the writing and editing of the manuscript. All authors read and approved this manuscript.

Funding

This research was funded by the Basic Science Research Program of the National Research Foundation of Korea (NRF), which is funded by the Ministry of Science, ICT & Future Planning (NRF-2018R1D1A3B07041059 to M.M. and NRF-2016R1A5A2012284 to Y.-M.P.), by the Cooperative Research Program for Agriculture Science and Technology Development (Project No. PJ01428603), Rural Development Administration, Republic of Korea, and by the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HF21C0021).

Availability of data and materials

Not applicable.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

Authors declare no competing interests.

Footnotes

Hyeon soo Kim, Sujin Kim, Soo Jung Shin and Yong Ho Park contributed equally to this work

Contributor Information

Hyun Duk Yang, Email: hyundyang@gmail.com.

Yeong-Min Park, Email: immun3023@kku.ac.kr.

Minho Moon, Email: hominmoon@konyang.ac.kr.

References

1.2020 Alzheimer's disease facts and figures. Alzheimers Dement 2020. [DOI] [PubMed]
2.De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV. Alzheimer's disease. Subcell Biochem. 2012;65:329–352. doi: 10.1007/978-94-007-5416-4_14. [DOI] [PubMed] [Google Scholar]
3.Jack CR, Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14:535–562. doi: 10.1016/j.jalz.2018.02.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
4.Mehta D, Jackson R, Paul G, Shi J, Sabbagh M. Why do trials for Alzheimer's disease drugs keep failing? A discontinued drug perspective for 2010–2015. Expert Opin Investig Drugs. 2017;26:735–739. doi: 10.1080/13543784.2017.1323868. [DOI] [PMC free article] [PubMed] [Google Scholar]
5.Mawanda F, Wallace R. Can infections cause Alzheimer's disease? Epidemiol Rev. 2013;35:161–180. doi: 10.1093/epirev/mxs007. [DOI] [PMC free article] [PubMed] [Google Scholar]
6.Abbott A. Are infections seeding some cases of Alzheimer's disease? Nature. 2020;587:22–25. doi: 10.1038/d41586-020-03084-9. [DOI] [PubMed] [Google Scholar]
7.Sochocka M, Zwolinska K, Leszek J. The infectious etiology of Alzheimer's disease. Curr Neuropharmacol. 2017;15:996–1009. doi: 10.2174/1570159X15666170313122937. [DOI] [PMC free article] [PubMed] [Google Scholar]
8.Kim SH, Noh MY, Kim HJ, Oh KW, Park J, Lee S, et al. A therapeutic strategy for Alzheimer's disease focused on immune-inflammatory modulation. Dement Neurocogn Disord. 2019;18:33–46. doi: 10.12779/dnd.2019.18.2.33. [DOI] [PMC free article] [PubMed] [Google Scholar]
9.Vogt NM, Kerby RL, Dill-McFarland KA, Harding SJ, Merluzzi AP, Johnson SC, et al. Gut microbiome alterations in Alzheimer's disease. Sci Rep. 2017;7:13537. doi: 10.1038/s41598-017-13601-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
10.Wang X, Sun G, Feng T, Zhang J, Huang X, Wang T, et al. Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer's disease progression. Cell Res. 2019;29:787–803. doi: 10.1038/s41422-019-0216-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
11.Pritchard AB, Crean S, Olsen I, Singhrao SK. Periodontitis, microbiomes and their role in Alzheimer's disease. Front Aging Neurosci. 2017;9:336. doi: 10.3389/fnagi.2017.00336. [DOI] [PMC free article] [PubMed] [Google Scholar]
12.Giau VV, Wu SY, Jamerlan A, An SSA, Kim SY, Hulme J. Gut microbiota and their neuroinflammatory implications in Alzheimer's disease. Nutrients. 2018;10:1765. doi: 10.3390/nu10111765. [DOI] [PMC free article] [PubMed] [Google Scholar]
13.Emery DC, Shoemark DK, Batstone TE, Waterfall CM, Coghill JA, Cerajewska TL, et al. 16S rRNA next generation sequencing analysis shows bacteria in Alzheimer's post-mortem brain. Front Aging Neurosci. 2017;9:195. doi: 10.3389/fnagi.2017.00195. [DOI] [PMC free article] [PubMed] [Google Scholar]
14.Jiang C, Li G, Huang P, Liu Z, Zhao B. The gut microbiota and Alzheimer's disease. J Alzheimers Dis. 2017;58:1–15. doi: 10.3233/JAD-161141. [DOI] [PubMed] [Google Scholar]
15.Zhan X, Stamova B, Jin LW, DeCarli C, Phinney B, Sharp FR. Gram-negative bacterial molecules associate with Alzheimer disease pathology. Neurology. 2016;87:2324–2332. doi: 10.1212/WNL.0000000000003391. [DOI] [PMC free article] [PubMed] [Google Scholar]
16.Pretorius E, Bester J, Kell DB. A bacterial component to Alzheimer's-type dementia seen via a systems biology approach that links iron dysregulation and inflammagen shedding to disease. J Alzheimers Dis. 2016;53:1237–1256. doi: 10.3233/JAD-160318. [DOI] [PMC free article] [PubMed] [Google Scholar]
17.Fulop T, Witkowski JM, Bourgade K, Khalil A, Zerif E, Larbi A, et al. Can an infection hypothesis explain the beta amyloid hypothesis of Alzheimer's disease? Front Aging Neurosci. 2018;10:224. doi: 10.3389/fnagi.2018.00224. [DOI] [PMC free article] [PubMed] [Google Scholar]
18.Brown GC. The endotoxin hypothesis of neurodegeneration. J Neuroinflammation. 2019;16:180. doi: 10.1186/s12974-019-1564-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
19.Hung YL, Fang SH, Wang SC, Cheng WC, Liu PL, Su CC, et al. Corylin protects LPS-induced sepsis and attenuates LPS-induced inflammatory response. Sci Rep. 2017;7:46299. doi: 10.1038/srep46299. [DOI] [PMC free article] [PubMed] [Google Scholar]
20.Chou CH, Lee JT, Lin CC, Sung YF, Lin CC, Muo CH, et al. Septicemia is associated with increased risk for dementia: a population-based longitudinal study. Oncotarget. 2017;8:84300–84308. doi: 10.18632/oncotarget.20899. [DOI] [PMC free article] [PubMed] [Google Scholar]
21.Iwashyna TJ, Ely EW, Smith DM, Langa KM. Long-term cognitive impairment and functional disability among survivors of severe sepsis. JAMA. 2010;304:1787–1794. doi: 10.1001/jama.2010.1553. [DOI] [PMC free article] [PubMed] [Google Scholar]
22.Zhang R, Miller RG, Gascon R, Champion S, Katz J, Lancero M, et al. Circulating endotoxin and systemic immune activation in sporadic amyotrophic lateral sclerosis (sALS) J Neuroimmunol. 2009;206:121–124. doi: 10.1016/j.jneuroim.2008.09.017. [DOI] [PMC free article] [PubMed] [Google Scholar]
23.Lee HJ, Lee KE, Kim JK, Kim DH. Suppression of gut dysbiosis by Bifidobacterium longum alleviates cognitive decline in 5XFAD transgenic and aged mice. Sci Rep. 2019;9:11814. doi: 10.1038/s41598-019-48342-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
24.Zhan X, Stamova B, Sharp FR. Lipopolysaccharide associates with amyloid plaques, neurons and oligodendrocytes in Alzheimer's disease brain: a review. Front Aging Neurosci. 2018;10:42. doi: 10.3389/fnagi.2018.00042. [DOI] [PMC free article] [PubMed] [Google Scholar]
25.Honjo K, van Reekum R, Verhoeff NP. Alzheimer's disease and infection: do infectious agents contribute to progression of Alzheimer's disease? Alzheimers Dement. 2009;5:348–360. doi: 10.1016/j.jalz.2008.12.001. [DOI] [PubMed] [Google Scholar]
26.Beydoun MA, Beydoun HA, Weiss J, Hossain S, El-Hajj ZW, Zonderman AB. Helicobacter pylori, periodontal pathogens, and their interactive association with incident all-cause and Alzheimer's disease dementia in a large national survey. Mol Psychiatry 2020. [DOI] [PubMed]
27.Beydoun MA, Beydoun HA, Hossain S, El-Hajj ZW, Weiss J, Zonderman AB. Clinical and bacterial markers of periodontitis and their association with incident all-cause and Alzheimer's disease dementia in a large national survey. J Alzheimers Dis. 2020;75:157–172. doi: 10.3233/JAD-200064. [DOI] [PMC free article] [PubMed] [Google Scholar]
28.Park J, Kim TJ, Song JH, Jang H, Kim JS, Kang SH, et al. Helicobacter pylori infection is associated with neurodegeneration in cognitively normal men. J Alzheimers Dis. 2021;82:1591–1599. doi: 10.3233/JAD-210119. [DOI] [PubMed] [Google Scholar]
29.Zilli EM, O'Donnell A, Salinas J, Aparicio HJ, Gonzales MM, Jacob M, Beiser A, et al. Herpes Labialis, Chlamydophila pneumoniae, Helicobacter pylori, and cytomegalovirus infections and risk of dementia: the framingham heart study. J Alzheimers Dis. 2021;82:593–605. doi: 10.3233/JAD-200957. [DOI] [PMC free article] [PubMed] [Google Scholar]
30.Fu P, Gao M, Yung KKL. Association of intestinal disorders with Parkinson's disease and Alzheimer's disease: a systematic review and meta-analysis. ACS Chem Neurosci. 2020;11:395–405. doi: 10.1021/acschemneuro.9b00607. [DOI] [PubMed] [Google Scholar]
31.Beydoun MA, Beydoun HA, Elbejjani M, Dore GA, Zonderman AB. Helicobacter pylori seropositivity and its association with incident all-cause and Alzheimer's disease dementia in large national surveys. Alzheimers Dement. 2018;14:1148–1158. doi: 10.1016/j.jalz.2018.04.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
32.Harach T, Marungruang N, Duthilleul N, Cheatham V, Mc Coy KD, Frisoni G, et al. Reduction of Abeta amyloid pathology in APPPS1 transgenic mice in the absence of gut microbiota. Sci Rep. 2017;7:41802. doi: 10.1038/srep41802. [DOI] [PMC free article] [PubMed] [Google Scholar]
33.Shen L, Liu L, Ji H-F. Alzheimer’s disease histological and behavioral manifestations in transgenic mice correlate with specific gut microbiome state. J Alzheimers Dis. 2017;56:385–390. doi: 10.3233/JAD-160884. [DOI] [PubMed] [Google Scholar]
34.Bauerl C, Collado MC, Diaz Cuevas A, Vina J, Perez Martinez G. Shifts in gut microbiota composition in an APP/PSS1 transgenic mouse model of Alzheimer's disease during lifespan. Lett Appl Microbiol. 2018;66:464–471. doi: 10.1111/lam.12882. [DOI] [PubMed] [Google Scholar]
35.Brandscheid C, Schuck F, Reinhardt S, Schafer KH, Pietrzik CU, Grimm M, et al. Altered gut microbiome composition and tryptic activity of the 5xFAD Alzheimer's mouse model. J Alzheimers Dis. 2017;56:775–788. doi: 10.3233/JAD-160926. [DOI] [PubMed] [Google Scholar]
36.MacIntyre A, Abramov R, Hammond CJ, Hudson AP, Arking EJ, Little CS, et al. Chlamydia pneumoniae infection promotes the transmigration of monocytes through human brain endothelial cells. J Neurosci Res. 2003;71:740–750. doi: 10.1002/jnr.10519. [DOI] [PubMed] [Google Scholar]
37.Arking EJ, Appelt DM, Abrams JT, Kolbe S, Hudson AP, Balin BJ. Ultrastructural analysis of Chlamydia pneumoniae in the Alzheimer's brain. Pathogenesis (Amst) 1999;1:201–211. [PMC free article] [PubMed] [Google Scholar]
38.Poole S, Singhrao SK, Kesavalu L, Curtis MA, Crean S. Determining the presence of periodontopathic virulence factors in short-term postmortem Alzheimer's disease brain tissue. J Alzheimers Dis. 2013;36:665–677. doi: 10.3233/JAD-121918. [DOI] [PubMed] [Google Scholar]
39.Huma Siddiqui ERE, Singhrao SK, Olsen I. High throughput sequencing detect gingivitis and periodontal oral bacteria in Alzheimer’s disease autopsy brains. Neuro Res. 2019;1:3. [Google Scholar]
40.Balin BJ, Gerard HC, Arking EJ, Appelt DM, Branigan PJ, Abrams JT, Whittum-Hudson JA, Hudson AP. Identification and localization of Chlamydia pneumoniae in the Alzheimer's brain. Med Microbiol Immunol. 1998;187:23–42. doi: 10.1007/s004300050071. [DOI] [PubMed] [Google Scholar]
41.Gerard HC, Dreses-Werringloer U, Wildt KS, Deka S, Oszust C, Balin BJ. Chlamydophila (Chlamydia) pneumoniae in the Alzheimer's brain. FEMS Immunol Med Microbiol. 2006;48:355–366. doi: 10.1111/j.1574-695X.2006.00154.x. [DOI] [PubMed] [Google Scholar]
42.Riviere GR, Riviere KH, Smith KS. Molecular and immunological evidence of oral Treponema in the human brain and their association with Alzheimer's disease. Oral Microbiol Immunol. 2002;17:113–118. doi: 10.1046/j.0902-0055.2001.00100.x. [DOI] [PubMed] [Google Scholar]
43.Gerard HC, Wildt KL, Whittum-Hudson JA, Lai Z, Ager J, Hudson AP. The load of Chlamydia pneumoniae in the Alzheimer's brain varies with APOE genotype. Microb Pathog. 2005;39:19–26. doi: 10.1016/j.micpath.2005.05.002. [DOI] [PubMed] [Google Scholar]
44.Miklossy J, Kasas S, Janzer RC, Ardizzoni F, Van der Loos H. Further ultrastructural evidence that spirochaetes may play a role in the aetiology of Alzheimer's disease. NeuroReport. 1994;5:1201–1204. doi: 10.1097/00001756-199406020-00010. [DOI] [PubMed] [Google Scholar]
45.Dreses-Werringloer U, Bhuiyan M, Zhao Y, Gerard HC, Whittum-Hudson JA, Hudson AP. Initial characterization of Chlamydophila (Chlamydia) pneumoniae cultured from the late-onset Alzheimer brain. Int J Med Microbiol. 2009;299:187–201. doi: 10.1016/j.ijmm.2008.07.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
46.Miklossy J, Khalili K, Gern L, Ericson RL, Darekar P, Bolle L, et al. Borrelia burgdorferi persists in the brain in chronic lyme neuroborreliosis and may be associated with Alzheimer disease. J Alzheimers Dis. 2004;6:639–649. doi: 10.3233/jad-2004-6608. [DOI] [PubMed] [Google Scholar]
47.Paradowski B, Jaremko M, Dobosz T, Leszek J, Noga L. Evaluation of CSF-Chlamydia pneumoniae, CSF-tau, and CSF-Abeta42 in Alzheimer's disease and vascular dementia. J Neurol. 2007;254:154–159. doi: 10.1007/s00415-006-0298-5. [DOI] [PubMed] [Google Scholar]
48.Kountouras J, Boziki M, Gavalas E, Zavos C, Deretzi G, Grigoriadis N, et al. Increased cerebrospinal fluid Helicobacter pylori antibody in Alzheimer's disease. Int J Neurosci. 2009;119:765–777. doi: 10.1080/00207450902782083. [DOI] [PubMed] [Google Scholar]
49.Miklossy J. Alzheimer's disease–a spirochetosis? NeuroReport. 1993;4:841–848. [PubMed] [Google Scholar]
50.Zhang L, Wang Y, Xiayu X, Shi C, Chen W, Song N, et al. Altered gut microbiota in a mouse model of Alzheimer's disease. J Alzheimers Dis. 2017;60:1241–1257. doi: 10.3233/JAD-170020. [DOI] [PubMed] [Google Scholar]
51.Chen C, Ahn EH, Kang SS, Liu X, Alam A, Ye K. Gut dysbiosis contributes to amyloid pathology, associated with C/EBPbeta/AEP signaling activation in Alzheimer's disease mouse model. Sci Adv. 2020;6:eaba0466. doi: 10.1126/sciadv.aba0466. [DOI] [PMC free article] [PubMed] [Google Scholar]
52.Bu XL, Yao XQ, Jiao SS, Zeng F, Liu YH, Xiang Y, et al. A study on the association between infectious burden and Alzheimer's disease. Eur J Neurol. 2015;22:1519–1525. doi: 10.1111/ene.12477. [DOI] [PubMed] [Google Scholar]
53.Herrera-Landero A, Amaya-Sánchez LE, De Las-Deses CD, Solórzano-Santos F, Gordillo-Pérez MG. Borrelia burgdorferi as a risk factor for Alzheimer’s dementia and mild cognitive impairment. European Geriatric Medicine. 2019;10:493–500. doi: 10.1007/s41999-018-0153-0. [DOI] [PubMed] [Google Scholar]
54.Al-Obaidi MMJ, Desa MNM. Mechanisms of blood brain barrier disruption by different types of bacteria, and bacterial-host interactions facilitate the bacterial pathogen invading the brain. Cell Mol Neurobiol. 2018;38:1349–1368. doi: 10.1007/s10571-018-0609-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
55.Zhou Y, Tao J, Yu H, Ni J, Zeng L, Teng Q, et al. Hcp family proteins secreted via the type VI secretion system coordinately regulate Escherichia coli K1 interaction with human brain microvascular endothelial cells. Infect Immun. 2012;80:1243–1251. doi: 10.1128/IAI.05994-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
56.Mittal R, Prasadarao NV. Nitric oxide/cGMP signalling induces Escherichia coli K1 receptor expression and modulates the permeability in human brain endothelial cell monolayers during invasion. Cell Microbiol. 2010;12:67–83. doi: 10.1111/j.1462-5822.2009.01379.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
57.Kristensson K. Microbes' roadmap to neurons. Nat Rev Neurosci. 2011;12:345–357. doi: 10.1038/nrn3029. [DOI] [PubMed] [Google Scholar]
58.Rodriguez Coyago ML, Sanchez Temino VE. Periodontitis determining the onset and progression of Huntington's disease: review of the literature. Medwave. 2015;15:e6293. doi: 10.5867/medwave.2015.09.6293. [DOI] [PubMed] [Google Scholar]
59.Dominy SS, Lynch C, Ermini F, Benedyk M, Marczyk A, Konradi A, et al. Porphyromonas gingivalis in Alzheimer's disease brains: evidence for disease causation and treatment with small-molecule inhibitors. Sci Adv. 2019;5:eaau3333. doi: 10.1126/sciadv.aau3333. [DOI] [PMC free article] [PubMed] [Google Scholar]
60.Poole S, Singhrao SK, Chukkapalli S, Rivera M, Velsko I, Kesavalu L, et al. Active invasion of Porphyromonas gingivalis and infection-induced complement activation in ApoE-/- mice brains. J Alzheimers Dis. 2015;43:67–80. doi: 10.3233/JAD-140315. [DOI] [PubMed] [Google Scholar]
61.Doulberis M, Kotronis G, Thomann R, Polyzos SA, Boziki M, Gialamprinou D, et al. Review: impact of Helicobacter pylori on Alzheimer's disease: what do we know so far? Helicobacter. 2018;23:12454. doi: 10.1111/hel.12454. [DOI] [PubMed] [Google Scholar]
62.Strandwitz P. Neurotransmitter modulation by the gut microbiota. Brain Res. 2018;1693:128–133. doi: 10.1016/j.brainres.2018.03.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
63.Carabotti M, Scirocco A, Maselli MA, Severi C. The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. Ann Gastroenterol. 2015;28:203–209. [PMC free article] [PubMed] [Google Scholar]
64.Ma Q, Xing C, Long W, Wang HY, Liu Q, Wang RF. Impact of microbiota on central nervous system and neurological diseases: the gut-brain axis. J Neuroinflammation. 2019;16:53. doi: 10.1186/s12974-019-1434-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
65.Liu S, Gao J, Zhu M, Liu K, Zhang HL. Gut microbiota and dysbiosis in Alzheimer's disease: implications for pathogenesis and treatment. Mol Neurobiol. 2020;57:5026–5043. doi: 10.1007/s12035-020-02073-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
66.Hill JM, Clement C, Pogue AI, Bhattacharjee S, Zhao Y, Lukiw WJ. Pathogenic microbes, the microbiome, and Alzheimer's disease (AD) Front Aging Neurosci. 2014;6:127. doi: 10.3389/fnagi.2014.00127. [DOI] [PMC free article] [PubMed] [Google Scholar]
67.Honarpisheh P, Reynolds CR, Blasco Conesa MP, Moruno Manchon JF, Putluri N, Bhattacharjee MB, Urayama A, McCullough LD, Ganesh BP. Dysregulated Gut Homeostasis Observed Prior to the Accumulation of the Brain Amyloid-beta in Tg2576 Mice. Int J Mol Sci. 2020;21:1711. doi: 10.3390/ijms21051711. [DOI] [PMC free article] [PubMed] [Google Scholar]
68.Schwartz K, Boles BR. Microbial amyloids–functions and interactions within the host. Curr Opin Microbiol. 2013;16:93–99. doi: 10.1016/j.mib.2012.12.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
69.Javed I, Zhang Z, Adamcik J, Andrikopoulos N, Li Y, Otzen DE, et al. Accelerated amyloid beta pathogenesis by bacterial amyloid FapC. Adv Sci. 2020;7:2001299. doi: 10.1002/advs.202001299. [DOI] [PMC free article] [PubMed] [Google Scholar]
70.Shewmaker F, McGlinchey RP, Thurber KR, McPhie P, Dyda F, Tycko R, et al. The functional curli amyloid is not based on in-register parallel beta-sheet structure. J Biol Chem. 2009;284:25065–25076. doi: 10.1074/jbc.M109.007054. [DOI] [PMC free article] [PubMed] [Google Scholar]
71.Hill JM, Lukiw WJ. Microbial-generated amyloids and Alzheimer's disease (AD) Front Aging Neurosci. 2015;7:9. doi: 10.3389/fnagi.2015.00009. [DOI] [PMC free article] [PubMed] [Google Scholar]
72.Chapman MR, Robinson LS, Pinkner JS, Roth R, Heuser J, Hammar M, et al. Role of Escherichia coli curli operons in directing amyloid fiber formation. Science. 2002;295:851–855. doi: 10.1126/science.1067484. [DOI] [PMC free article] [PubMed] [Google Scholar]
73.Zhao Y, Dua P, Lukiw WJ. Microbial sources of amyloid and relevance to amyloidogenesis and Alzheimer's disease (AD) J Alzheimers Dis Parkinsonism. 2015;5:177. doi: 10.4172/2161-0460.1000177. [DOI] [PMC free article] [PubMed] [Google Scholar]
74.Friedland RP, Chapman MR. The role of microbial amyloid in neurodegeneration. PLOS Pathog. 2017;13:e1006654. doi: 10.1371/journal.ppat.1006654. [DOI] [PMC free article] [PubMed] [Google Scholar]
75.Oskarsson ME, Paulsson JF, Schultz SW, Ingelsson M, Westermark P, Westermark GT. In vivo seeding and cross-seeding of localized amyloidosis: a molecular link between type 2 diabetes and Alzheimer disease. Am J Pathol. 2015;185:834–846. doi: 10.1016/j.ajpath.2014.11.016. [DOI] [PubMed] [Google Scholar]
76.Moreno-Gonzalez I, Edwards Iii G, Salvadores N, Shahnawaz M, Diaz-Espinoza R, Soto C. Molecular interaction between type 2 diabetes and Alzheimer's disease through cross-seeding of protein misfolding. Mol Psychiatry. 2017;22:1327–1334. doi: 10.1038/mp.2016.230. [DOI] [PMC free article] [PubMed] [Google Scholar]
77.Cherny I, Rockah L, Levy-Nissenbaum O, Gophna U, Ron EZ, Gazit E. The formation of Escherichia coli curli amyloid fibrils is mediated by prion-like peptide repeats. J Mol Biol. 2005;352:245–252. doi: 10.1016/j.jmb.2005.07.028. [DOI] [PubMed] [Google Scholar]
78.Yan Z, Yin M, Chen J, Li X. Assembly and substrate recognition of curli biogenesis system. Nat Commun. 2020;11:241. doi: 10.1038/s41467-019-14145-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
79.Van Gerven N, Klein RD, Hultgren SJ, Remaut H. Bacterial amyloid formation: structural insights into curli biogensis. Trends Microbiol. 2015;23:693–706. doi: 10.1016/j.tim.2015.07.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
80.Shu Q, Crick SL, Pinkner JS, Ford B, Hultgren SJ, Frieden C. The E. coli CsgB nucleator of curli assembles to beta-sheet oligomers that alter the CsgA fibrillization mechanism. Proc Natl Acad Sci USA. 2012;109:6502–6507. doi: 10.1073/pnas.1204161109. [DOI] [PMC free article] [PubMed] [Google Scholar]
81.Dueholm MS, Petersen SV, Sonderkaer M, Larsen P, Christiansen G, Hein KL, et al. Functional amyloid in pseudomonas. Mol Microbiol. 2010;77:1009–1020. doi: 10.1111/j.1365-2958.2010.07269.x. [DOI] [PubMed] [Google Scholar]
82.Javed I, Zhang Z, Adamcik J, Andrikopoulos N, Li Y, Otzen DE, et al. Accelerated amyloid beta pathogenesis by bacterial amyloid FapC. Adv Sci (Weinh) 2020;7:2001299. doi: 10.1002/advs.202001299. [DOI] [PMC free article] [PubMed] [Google Scholar]
83.Rapsinski GJ, Newman TN, Oppong GO, van Putten JP, Tukel C. CD14 protein acts as an adaptor molecule for the immune recognition of Salmonella curli fibers. J Biol Chem. 2013;288:14178–14188. doi: 10.1074/jbc.M112.447060. [DOI] [PMC free article] [PubMed] [Google Scholar]
84.Shin MG, Lee JW, Han JS, Lee B, Jeong JH, Park SH, et al. Bacteria-derived metabolite, methylglyoxal, modulates the longevity of C. elegans through TORC2/SGK-1/DAF-16 signaling. Proc Natl Acad Sci USA. 2020;117:17142–17150. doi: 10.1073/pnas.1915719117. [DOI] [PMC free article] [PubMed] [Google Scholar]
85.Krautwald M, Munch G. Advanced glycation end products as biomarkers and gerontotoxins: a basis to explore methylglyoxal-lowering agents for Alzheimer's disease? Exp Gerontol. 2010;45:744–751. doi: 10.1016/j.exger.2010.03.001. [DOI] [PubMed] [Google Scholar]
86.Cho HJ, Son SM, Jin SM, Hong HS, Shin DH, Kim SJ, et al. RAGE regulates BACE1 and Abeta generation via NFAT1 activation in Alzheimer's disease animal model. FASEB J. 2009;23:2639–2649. doi: 10.1096/fj.08-126383. [DOI] [PubMed] [Google Scholar]
87.Ilievski V, Zuchowska PK, Green SJ, Toth PT, Ragozzino ME, Le K, et al. Chronic oral application of a periodontal pathogen results in brain inflammation, neurodegeneration and amyloid beta production in wild type mice. PLOS One. 2018;13:e0204941. doi: 10.1371/journal.pone.0204941. [DOI] [PMC free article] [PubMed] [Google Scholar]
88.Armbrust F, Colmorgen C, Pietrzik CU, Becker-Pauly C. The Alzheimer’s disease associated bacterial protease RgpB from P. gingivalis activates the alternative β-secretase meprin β thereby increasing Aβ generation. bioRxiv 2019;748814. 10.1101/748814
89.Li XH, Xie JZ, Jiang X, Lv BL, Cheng XS, Du LL, et al. Methylglyoxal induces tau hyperphosphorylation via promoting AGEs formation. Neuromol Med. 2012;14:338–348. doi: 10.1007/s12017-012-8191-0. [DOI] [PubMed] [Google Scholar]
90.Cadamuro AC, Rossi AF, Maniezzo NM, Silva AE. Helicobacter pylori infection: host immune response, implications on gene expression and microRNAs. World J Gastroenterol. 2014;20:1424–1437. doi: 10.3748/wjg.v20.i6.1424. [DOI] [PMC free article] [PubMed] [Google Scholar]
91.de Bernard M, Moschioni M, Papini E, Telford J, Rappuoli R, Montecucco C. Cell vacuolization induced by Helicobacter pylori VacA toxin: cell line sensitivity and quantitative estimation. Toxicol Lett. 1998;99:109–115. doi: 10.1016/s0378-4274(98)00140-4. [DOI] [PubMed] [Google Scholar]
92.Kumar H, Jo MJ, Choi H, Muttigi MS, Shon S, Kim BJ, et al. Matrix metalloproteinase-8 inhibition prevents disruption of blood-spinal cord barrier and attenuates inflammation in rat model of spinal cord injury. Mol Neurobiol. 2018;55:2577–2590. doi: 10.1007/s12035-017-0509-3. [DOI] [PubMed] [Google Scholar]
93.Blank M, Bashi T, Lachnish J, Ben-Ami-Shor D, Shovman O, Fridkin M, et al. Helminths-based bi-functional molecule, tuftsin-phosphorylcholine (TPC), ameliorates an established murine arthritis. PLOS ONE. 2018;13:e0200615. doi: 10.1371/journal.pone.0200615. [DOI] [PMC free article] [PubMed] [Google Scholar]
94.Erny D, de Angelis ALH, Jaitin D, Wieghofer P, Staszewski O, David E, et al. Host microbiota constantly control maturation and function of microglia in the CNS. Nat Neurosci. 2015;18:965–977. doi: 10.1038/nn.4030. [DOI] [PMC free article] [PubMed] [Google Scholar]
95.Colombo AV, Sadler RK, Llovera G, Singh V, Roth S, Heindl S, et al. Microbiota-derived short chain fatty acids modulate microglia and promote Aβ plaque deposition. eLife. 2021;10:e59826. doi: 10.7554/eLife.59826. [DOI] [PMC free article] [PubMed] [Google Scholar]
96.Marizzoni M, Cattaneo A, Mirabelli P, Festari C, Lopizzo N, Nicolosi V, et al. Short-chain fatty acids and lipopolysaccharide as mediators between gut dysbiosis and amyloid pathology in Alzheimer's disease. J Alzheimers Dis. 2020;78(2):683–697. doi: 10.3233/JAD-200306. [DOI] [PubMed] [Google Scholar]
97.Rothhammer V, Mascanfroni ID, Bunse L, Takenaka MC, Kenison JE, Mayo L, et al. Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor. Nat Med. 2016;22:586–597. doi: 10.1038/nm.4106. [DOI] [PMC free article] [PubMed] [Google Scholar]
98.Iqbal K, Liu F, Gong CX, Grundke-Iqbal I. Tau in Alzheimer disease and related tauopathies. Curr Alzheimer Res. 2010;7:656–664. doi: 10.2174/156720510793611592. [DOI] [PMC free article] [PubMed] [Google Scholar]
99.Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem. 1986;261:6084–6089. [PubMed] [Google Scholar]
100.Khlistunova I, Biernat J, Wang Y, Pickhardt M, von Bergen M, Gazova Z, et al. Inducible expression of Tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs. J Biol Chem. 2006;281:1205–1214. doi: 10.1074/jbc.M507753200. [DOI] [PubMed] [Google Scholar]
101.Ferrer I, Gomez-Isla T, Puig B, Freixes M, Ribe E, Dalfo E, Avila J. Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies. Curr Alzheimer Res. 2005;2:3–18. doi: 10.2174/1567205052772713. [DOI] [PubMed] [Google Scholar]
102.Wang XL, Zeng J, Yang Y, Xiong Y, Zhang ZH, Qiu M, Yan X, Sun XY, Tuo QZ, Liu R, Wang JZ. Helicobacter pylori filtrate induces Alzheimer-like tau hyperphosphorylation by activating glycogen synthase kinase-3beta. J Alzheimers Dis. 2015;43:153–165. doi: 10.3233/JAD-140198. [DOI] [PubMed] [Google Scholar]
103.Haditsch U, Roth T, Rodriguez L, Hancock S, Cecere T, Nguyen M, Arastu-Kapur S, Broce S, Raha D, Lynch CC, et al. Alzheimer's disease-like neurodegeneration in Porphyromonas gingivalis infected neurons with persistent expression of active gingipains. J Alzheimers Dis. 2020;75:1361–1376. doi: 10.3233/JAD-200393. [DOI] [PMC free article] [PubMed] [Google Scholar]
104.Kanagasingam S, Chukkapalli SS, Welbury R, Singhrao SK. Porphyromonas gingivalis is a strong risk factor for Alzheimer's disease. J Alzheimers Dis Rep. 2020;4:501–511. doi: 10.3233/ADR-200250. [DOI] [PMC free article] [PubMed] [Google Scholar]
105.Chu J, Lauretti E, Pratico D. Caspase-3-dependent cleavage of Akt modulates tau phosphorylation via GSK3beta kinase: implications for Alzheimer's disease. Mol Psychiatry. 2017;22:1002–1008. doi: 10.1038/mp.2016.214. [DOI] [PubMed] [Google Scholar]
106.Kovacech B, Novak M. Tau truncation is a productive posttranslational modification of neurofibrillary degeneration in Alzheimer's disease. Curr Alzheimer Res. 2010;7:708–716. doi: 10.2174/156720510793611556. [DOI] [PubMed] [Google Scholar]
107.Yin H, Kuret J. C-terminal truncation modulates both nucleation and extension phases of tau fibrillization. FEBS Lett. 2006;580:211–215. doi: 10.1016/j.febslet.2005.11.077. [DOI] [PubMed] [Google Scholar]
108.Taniguchi-Watanabe S, Arai T, Kametani F, Nonaka T, Masuda-Suzukake M, Tarutani A, et al. Biochemical classification of tauopathies by immunoblot, protein sequence and mass spectrometric analyses of sarkosyl-insoluble and trypsin-resistant tau. Acta Neuropathol. 2016;131:267–280. doi: 10.1007/s00401-015-1503-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
109.Tetz G, Pinho M, Pritzkow S, Mendez N, Soto C, Tetz V. Bacterial DNA promotes Tau aggregation. Sci Rep. 2020;10:2369. doi: 10.1038/s41598-020-59364-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
110.Regen F, Hellmann-Regen J, Costantini E, Reale M. Neuroinflammation and Alzheimer's disease: implications for microglial activation. Curr Alzheimer Res. 2017;14:1140–1148. doi: 10.2174/1567205014666170203141717. [DOI] [PubMed] [Google Scholar]
111.Kinney JW, Bemiller SM, Murtishaw AS, Leisgang AM, Salazar AM, Lamb BT. Inflammation as a central mechanism in Alzheimer's disease. Alzheimers Dement (N Y) 2018;4:575–590. doi: 10.1016/j.trci.2018.06.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
112.Dickson K, Lehmann C. Inflammatory response to different toxins in experimental sepsis models. Int J Mol Sci. 2019;20:4341. doi: 10.3390/ijms20184341. [DOI] [PMC free article] [PubMed] [Google Scholar]
113.McManus RM, Higgins SC, Mills KH, Lynch MA. Respiratory infection promotes T cell infiltration and amyloid-beta deposition in APP/PS1 mice. Neurobiol Aging. 2014;35:109–121. doi: 10.1016/j.neurobiolaging.2013.07.025. [DOI] [PubMed] [Google Scholar]
114.Balin BJ, Hammond CJ, Little CS, Hingley ST, Al-Atrache Z, Appelt DM, et al. Chlamydia pneumoniae: an etiologic agent for late-onset dementia. Front Aging Neurosci. 2018;10:302. doi: 10.3389/fnagi.2018.00302. [DOI] [PMC free article] [PubMed] [Google Scholar]
115.Ikejima H, Friedman H, Yamamoto Y. Chlamydia pneumoniae infection of microglial cells in vitro: a model of microbial infection for neurological disease. J Med Microbiol. 2006;55:947–952. doi: 10.1099/jmm.0.46348-0. [DOI] [PubMed] [Google Scholar]
116.Tajes M, Eraso-Pichot A, Rubio-Moscardo F, Guivernau B, Ramos-Fernandez E, Bosch-Morato M, et al. Methylglyoxal produced by amyloid-beta peptide-induced nitrotyrosination of triosephosphate isomerase triggers neuronal death in Alzheimer's disease. J Alzheimers Dis. 2014;41:273–288. doi: 10.3233/JAD-131685. [DOI] [PubMed] [Google Scholar]
117.Tajes M, Eraso-Pichot A, Rubio-Moscardo F, Guivernau B, Bosch-Morato M, Valls-Comamala V, et al. Methylglyoxal reduces mitochondrial potential and activates Bax and caspase-3 in neurons: implications for Alzheimer's disease. Neurosci Lett. 2014;580:78–82. doi: 10.1016/j.neulet.2014.07.047. [DOI] [PubMed] [Google Scholar]
118.Calvo-Rodriguez M, Garcia-Rodriguez C, Villalobos C, Nunez L. Role of toll like receptor 4 in Alzheimer's disease. Front Immunol. 2020;11:1588. doi: 10.3389/fimmu.2020.01588. [DOI] [PMC free article] [PubMed] [Google Scholar]
119.Li Y, Zhang L, Tang J, Yang X, Huang J, Zhu T, et al. Role of toll-like receptor 4 in the regulation of the cell death pathway and neuroinflammation. Brain Res Bull. 2019;148:79–90. doi: 10.1016/j.brainresbull.2019.03.015. [DOI] [PubMed] [Google Scholar]
120.d'Hennezel E, Abubucker S, Murphy LO, Cullen TW. Total Lipopolysaccharide from the Human Gut Microbiome Silences Toll-Like Receptor Signaling. Msystems. 2017;2:e00046-17. doi: 10.1128/mSystems.00046-17. [DOI] [PMC free article] [PubMed] [Google Scholar]
121.Guo S, Al-Sadi R, Said HM, Ma TY. Lipopolysaccharide causes an increase in intestinal tight junction permeability in vitro and in vivo by inducing enterocyte membrane expression and localization of TLR-4 and CD14. Am J Pathol. 2013;182:375–387. doi: 10.1016/j.ajpath.2012.10.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
122.Ghosh SS, Wang J, Yannie PJ, Ghosh S. Intestinal barrier dysfunction, LPS translocation, and disease development. J Endocr Soc. 2020;4:bvz039. doi: 10.1210/jendso/bvz039. [DOI] [PMC free article] [PubMed] [Google Scholar]
123.Zhao Y, Jaber V, Lukiw WJ. Secretory products of the human GI tract microbiome and their potential impact on Alzheimer's disease (AD): detection of lipopolysaccharide (LPS) in AD hippocampus. Front Cell Infect Microbiol. 2017;7:318. doi: 10.3389/fcimb.2017.00318. [DOI] [PMC free article] [PubMed] [Google Scholar]
124.Zhao Y, Cong L, Lukiw WJ. Lipopolysaccharide (LPS) accumulates in neocortical neurons of Alzheimer's disease (AD) brain and impairs transcription in human neuronal-glial primary co-cultures. Front Aging Neurosci. 2017;9:407. doi: 10.3389/fnagi.2017.00407. [DOI] [PMC free article] [PubMed] [Google Scholar]
125.Zhao Y, Cong L, Jaber V, Lukiw WJ. Microbiome-derived lipopolysaccharide enriched in the perinuclear region of Alzheimer's disease brain. Front Immunol. 2017;8:1064. doi: 10.3389/fimmu.2017.01064. [DOI] [PMC free article] [PubMed] [Google Scholar]
126.Vargas-Caraveo A, Sayd A, Maus SR, Caso JR, Madrigal JLM, Garcia-Bueno B, et al. Lipopolysaccharide enters the rat brain by a lipoprotein-mediated transport mechanism in physiological conditions. Sci Rep. 2017;7:13113. doi: 10.1038/s41598-017-13302-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
127.Gotsch U, Jager U, Dominis M, Vestweber D. Expression of P-selectin on endothelial cells is upregulated by LPS and TNF-alpha in vivo. Cell Adhes Commun. 1994;2:7–14. doi: 10.3109/15419069409014198. [DOI] [PubMed] [Google Scholar]
128.Meena M, Cools N. On the road to new treatments for multiple sclerosis: targeting dendritic cell migration into the central nervous system. Neural Regen Res. 2019;14:2088–2090. doi: 10.4103/1673-5374.262583. [DOI] [PMC free article] [PubMed] [Google Scholar]
129.Coisne C, Dehouck L, Faveeuw C, Delplace Y, Miller F, Landry C, et al. Mouse syngenic in vitro blood-brain barrier model: a new tool to examine inflammatory events in cerebral endothelium. Lab Invest. 2005;85:734–746. doi: 10.1038/labinvest.3700281. [DOI] [PubMed] [Google Scholar]
130.Varatharaj A, Galea I. The blood-brain barrier in systemic inflammation. Brain Behav Immun. 2017;60:1–12. doi: 10.1016/j.bbi.2016.03.010. [DOI] [PubMed] [Google Scholar]
131.Nonaka N, Shioda S, Banks WA. Effect of lipopolysaccharide on the transport of pituitary adenylate cyclase activating polypeptide across the blood-brain barrier. Exp Neurol. 2005;191:137–144. doi: 10.1016/j.expneurol.2004.09.013. [DOI] [PubMed] [Google Scholar]
132.Woodcock TE, Woodcock TM. Revised Starling equation and the glycocalyx model of transvascular fluid exchange: an improved paradigm for prescribing intravenous fluid therapy. Br J Anaesth. 2012;108:384–394. doi: 10.1093/bja/aer515. [DOI] [PubMed] [Google Scholar]
133.Heinbockel L, Weindl G, Martinez-de-Tejada G, Correa W, Sanchez-Gomez S, Barcena-Varela S, et al. Inhibition of lipopolysaccharide- and lipoprotein-induced inflammation by antitoxin peptide pep19–2.5. Front Immunol. 2018;9:1704. doi: 10.3389/fimmu.2018.01704. [DOI] [PMC free article] [PubMed] [Google Scholar]
134.Le Guennec L, Coureuil M, Nassif X, Bourdoulous S. Strategies used by bacterial pathogens to cross the blood-brain barrier. Cell Microbiol. 2020;22:e13132. doi: 10.1111/cmi.13132. [DOI] [PubMed] [Google Scholar]
135.Pfalzgraff A, Correa W, Heinbockel L, Schromm AB, Lubow C, Gisch N, et al. LPS-neutralizing peptides reduce outer membrane vesicle-induced inflammatory responses. Biochim Biophys Acta Mol Cell Biol Lipids. 2019;1864:1503–1513. doi: 10.1016/j.bbalip.2019.05.018. [DOI] [PubMed] [Google Scholar]
136.Lee HJ, Hwang YH, Kim DH. Lactobacillus plantarum C29-fermented soybean (DW2009) alleviates memory impairment in 5XFAD transgenic mice by regulating microglia activation and gut microbiota composition. Mol Nutr Food Res. 2018;62:e1800359. doi: 10.1002/mnfr.201800359. [DOI] [PubMed] [Google Scholar]
137.Kirk RA, Kesner RP, Wang LM, Wu Q, Towner RA, Hoffman JM, et al. Lipopolysaccharide exposure in a rat sepsis model results in hippocampal amyloid-beta plaque and phosphorylated tau deposition and corresponding behavioral deficits. Geroscience. 2019;41:467–481. doi: 10.1007/s11357-019-00089-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
138.Lee JW, Lee YK, Yuk DY, Choi DY, Ban SB, Oh KW, et al. Neuro-inflammation induced by lipopolysaccharide causes cognitive impairment through enhancement of beta-amyloid generation. J Neuroinflammation. 2008;5:37. doi: 10.1186/1742-2094-5-37. [DOI] [PMC free article] [PubMed] [Google Scholar]
139.Wu Z, Ni J, Liu Y, Teeling JL, Takayama F, Collcutt A, et al. Cathepsin B plays a critical role in inducing Alzheimer's disease-like phenotypes following chronic systemic exposure to lipopolysaccharide from Porphyromonas gingivalis in mice. Brain Behav Immun. 2017;65:350–361. doi: 10.1016/j.bbi.2017.06.002. [DOI] [PubMed] [Google Scholar]
140.Deng X, Li M, Ai W, He L, Lu D, Patrylo PR, et al. Lipolysaccharide-induced neuroinflammation is associated with alzheimer-like amyloidogenic axonal pathology and dendritic degeneration in rats. Adv Alzheimer Dis. 2014;3:78–93. doi: 10.4236/aad.2014.32009. [DOI] [PMC free article] [PubMed] [Google Scholar]
141.Wang LM, Wu Q, Kirk RA, Horn KP, Ebada Salem AH, Hoffman JM, et al. Lipopolysaccharide endotoxemia induces amyloid-beta and p-tau formation in the rat brain. Am J Nucl Med Mol Imaging. 2018;8:86–99. [PMC free article] [PubMed] [Google Scholar]
142.Erickson MA, Hartvigson PE, Morofuji Y, Owen JB, Butterfield DA, Banks WA. Lipopolysaccharide impairs amyloid beta efflux from brain: altered vascular sequestration, cerebrospinal fluid reabsorption, peripheral clearance and transporter function at the blood-brain barrier. J Neuroinflammation. 2012;9:150. doi: 10.1186/1742-2094-9-150. [DOI] [PMC free article] [PubMed] [Google Scholar]
143.Sy M, Kitazawa M, Medeiros R, Whitman L, Cheng D, Lane TE, et al. Inflammation induced by infection potentiates tau pathological features in transgenic mice. Am J Pathol. 2011;178:2811–2822. doi: 10.1016/j.ajpath.2011.02.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
144.Kitazawa M, Oddo S, Yamasaki TR, Green KN, LaFerla FM. Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J Neurosci. 2005;25:8843–8853. doi: 10.1523/JNEUROSCI.2868-05.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
145.Bahar B, Singhrao SK. An evaluation of the molecular mode of action of trans-resveratrol in the Porphyromonas gingivalis lipopolysaccharide challenged neuronal cell model. Mol Biol Rep. 2021;48:147–156. doi: 10.1007/s11033-020-06024-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
146.Liu J, Wang D, Li SQ, Yu Y, Ye RD. Suppression of LPS-induced tau hyperphosphorylation by serum amyloid A. J Neuroinflammation. 2016;13:28. doi: 10.1186/s12974-016-0493-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
147.Roe AD, Staup MA, Serrats J, Sawchenko PE, Rissman RA. Lipopolysaccharide-induced tau phosphorylation and kinase activity–modulation, but not mediation, by corticotropin-releasing factor receptors. Eur J Neurosci. 2011;34:448–456. doi: 10.1111/j.1460-9568.2011.07764.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
148.Barron M, Gartlon J, Dawson LA, Atkinson PJ, Pardon MC. A state of delirium: deciphering the effect of inflammation on tau pathology in Alzheimer's disease. Exp Gerontol. 2017;94:103–107. doi: 10.1016/j.exger.2016.12.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
149.Rangasamy SB, Jana M, Roy A, Corbett GT, Kundu M, Chandra S, et al. Selective disruption of TLR2-MyD88 interaction inhibits inflammation and attenuates Alzheimer's pathology. J Clin Invest. 2018;128:4297–4312. doi: 10.1172/JCI96209. [DOI] [PMC free article] [PubMed] [Google Scholar]
150.Kim BW, Koppula S, Hong SS, Jeon SB, Kwon JH, Hwang BY, et al. Regulation of microglia activity by glaucocalyxin-A: attenuation of lipopolysaccharide-stimulated neuroinflammation through NF-kappaB and p38 MAPK signaling pathways. PLoS One. 2013;8:e55792. doi: 10.1371/journal.pone.0055792. [DOI] [PMC free article] [PubMed] [Google Scholar]
151.McCarthy GM, Bridges CR, Blednov YA, Harris RA. CNS cell-type localization and LPS response of TLR signaling pathways. F1000Res. 2017;6:1144. doi: 10.12688/f1000research.12036.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
152.Mizobuchi H, Soma GI. Low-dose lipopolysaccharide as an immune regulator for homeostasis maintenance in the central nervous system through transformation to neuroprotective microglia. Neural Regen Res. 2021;16:1928–1934. doi: 10.4103/1673-5374.308067. [DOI] [PMC free article] [PubMed] [Google Scholar]
153.Jendresen C, Digre A, Cui H, Zhang X, Vlodavsky I, Li JP, et al. Systemic LPS-induced Abeta-solubilization and clearance in AbetaPP-transgenic mice is diminished by heparanase overexpression. Sci Rep. 2019;9:4600. doi: 10.1038/s41598-019-40999-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
154.Go M, Kou J, Lim JE, Yang J, Fukuchi KI. Microglial response to LPS increases in wild-type mice during aging but diminishes in an Alzheimer's mouse model: implication of TLR4 signaling in disease progression. Biochem Biophys Res Commun. 2016;479:331–337. doi: 10.1016/j.bbrc.2016.09.073. [DOI] [PMC free article] [PubMed] [Google Scholar]
155.Quinn J, Montine T, Morrow J, Woodward WR, Kulhanek D, Eckenstein F. Inflammation and cerebral amyloidosis are disconnected in an animal model of Alzheimer's disease. J Neuroimmunol. 2003;137:32–41. doi: 10.1016/s0165-5728(03)00037-7. [DOI] [PubMed] [Google Scholar]
156.Thygesen C, Ilkjaer L, Kempf SJ, Hemdrup AL, von Linstow CU, Babcock AA, et al. Diverse protein profiles in CNS myeloid cells and CNS tissue from lipopolysaccharide- and vehicle-injected APPSWE/PS1DeltaE9 transgenic mice implicate Cathepsin Z in Alzheimer's disease. Front Cell Neurosci. 2018;12:397. doi: 10.3389/fncel.2018.00397. [DOI] [PMC free article] [PubMed] [Google Scholar]
157.Piao W, Song C, Chen H, Diaz MA, Wahl LM, Fitzgerald KA, et al. Endotoxin tolerance dysregulates MyD88- and Toll/IL-1R domain-containing adapter inducing IFN-beta-dependent pathways and increases expression of negative regulators of TLR signaling. J Leukoc Biol. 2009;86:863–875. doi: 10.1189/jlb.0309189. [DOI] [PMC free article] [PubMed] [Google Scholar]
158.Lee DC, Rizer J, Selenica ML, Reid P, Kraft C, Johnson A, et al. LPS- induced inflammation exacerbates phospho-tau pathology in rTg4510 mice. J Neuroinflammation. 2010;7:56. doi: 10.1186/1742-2094-7-56. [DOI] [PMC free article] [PubMed] [Google Scholar]
159.Zhou J, Yu W, Zhang M, Tian X, Li Y, Lu Y. Imbalance of microglial TLR4/TREM2 in LPS-treated APP/PS1 transgenic mice: a potential link between Alzheimer's disease and systemic inflammation. Neurochem Res. 2019;44:1138–1151. doi: 10.1007/s11064-019-02748-x. [DOI] [PubMed] [Google Scholar]
160.Drake L, Scott P. Investigation into RAGE as a biomarker of the LPS-induced murine model of neuroinflammation. J Nucl Med. 2019;60:480–480. [Google Scholar]
161.Cai Z, Liu N, Wang C, Qin B, Zhou Y, Xiao M, et al. Role of RAGE in Alzheimer's disease. Cell Mol Neurobiol. 2016;36:483–495. doi: 10.1007/s10571-015-0233-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
162.Fang F, Lue LF, Yan S, Xu H, Luddy JS, Chen D, et al. RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease. FASEB J. 2010;24:1043–1055. doi: 10.1096/fj.09-139634. [DOI] [PMC free article] [PubMed] [Google Scholar]
163.Wang L, Wu J, Guo X, Huang X, Huang Q. RAGE plays a role in LPS-induced NF-kappaB activation and endothelial hyperpermeability. Sensors (Basel) 2017;17:722. doi: 10.3390/s17040722. [DOI] [PMC free article] [PubMed] [Google Scholar]
164.Loffredo L, Ettorre E, Zicari AM, Inghilleri M, Nocella C, Perri L, et al. Oxidative stress and gut-derived lipopolysaccharides in neurodegenerative disease: role of NOX2. Oxid Med Cell Longev. 2020;2020:8630275. doi: 10.1155/2020/8630275. [DOI] [PMC free article] [PubMed] [Google Scholar]
165.Zhang Y, Feng S, Nie K, Li Y, Gao Y, Gan R, et al. TREM2 modulates microglia phenotypes in the neuroinflammation of Parkinson's disease. Biochem Biophys Res Commun. 2018;499:797–802. doi: 10.1016/j.bbrc.2018.03.226. [DOI] [PubMed] [Google Scholar]
166.Kim S, Chung H, Ngoc Mai H, Nam Y, Shin SJ, Park YH, et al. Low-dose ionizing radiation modulates microglia phenotypes in the models of Alzheimer’s disease. Int J Mol Sci. 2020;21:4532. doi: 10.3390/ijms21124532. [DOI] [PMC free article] [PubMed] [Google Scholar]
167.Zhao J, Bi W, Xiao S, Lan X, Cheng X, Zhang J, et al. Neuroinflammation induced by lipopolysaccharide causes cognitive impairment in mice. Sci Rep. 2019;9:5790. doi: 10.1038/s41598-019-42286-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
168.Sheppard O, Coleman MP, Durrant CS. Lipopolysaccharide-induced neuroinflammation induces presynaptic disruption through a direct action on brain tissue involving microglia-derived interleukin 1 beta. J Neuroinflammation. 2019;16:1–13. doi: 10.1186/s12974-019-1490-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
169.Abareshi A, Anaeigoudari A, Norouzi F, Shafei MN, Boskabady MH, Khazaei M, et al. Lipopolysaccharide-induced spatial memory and synaptic plasticity impairment is preventable by captopril. Advances in medicine. 2016;2016:1–8. doi: 10.1155/2016/7676512. [DOI] [PMC free article] [PubMed] [Google Scholar]
170.Xin Y, Jiang J, Hu Y, Pan J, Mi X, Gao Q, et al. Immune system drives synapse loss during LPS-induced learning and memory impairment in mice. Front. Aging Neurosci. 2019;11:279. doi: 10.3389/fnagi.2019.00279. [DOI] [PMC free article] [PubMed] [Google Scholar]
171.Chugh D, Nilsson P, Afjei S-A, Bakochi A, Ekdahl CT. Brain inflammation induces post-synaptic changes during early synapse formation in adult-born hippocampal neurons. Exp Neurol. 2013;250:176–188. doi: 10.1016/j.expneurol.2013.09.005. [DOI] [PubMed] [Google Scholar]
172.Zhan X, Stamova B, Sharp FR. Lipopolysaccharide associates with amyloid plaques, neurons and oligodendrocytes in Alzheimer’s disease brain: a review. Front. Aging Neurosci. 2018;10:42. doi: 10.3389/fnagi.2018.00042. [DOI] [PMC free article] [PubMed] [Google Scholar]
173.Xing B, Bachstetter AD, Van Eldik LJ. Microglial p38α MAPK is critical for LPS-induced neuron degeneration, through a mechanism involving TNFα. Mol Neurodegener. 2011;6:1–12. doi: 10.1186/1750-1326-6-84. [DOI] [PMC free article] [PubMed] [Google Scholar]
174.Bachstetter AD, Xing B, de Almeida L, Dimayuga ER, Watterson DM, Van Eldik LJ. Microglial p38alpha MAPK is a key regulator of proinflammatory cytokine up-regulation induced by toll-like receptor (TLR) ligands or beta-amyloid (Abeta) J Neuroinflammation. 2011;8:79. doi: 10.1186/1742-2094-8-79. [DOI] [PMC free article] [PubMed] [Google Scholar]
175.Qin L, Liu Y, Hong JS, Crews FT. NADPH oxidase and aging drive microglial activation, oxidative stress, and dopaminergic neurodegeneration following systemic LPS administration. Glia. 2013;61:855–868. doi: 10.1002/glia.22479. [DOI] [PMC free article] [PubMed] [Google Scholar]
176.Ma MW, Wang J, Zhang Q, Wang R, Dhandapani KM, Vadlamudi RK, et al. NADPH oxidase in brain injury and neurodegenerative disorders. Mol Neurodegener. 2017;12:7. doi: 10.1186/s13024-017-0150-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
177.Fragoso-Morales LG, Correa-Basurto J, Rosales-Hernandez MC. Implication of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and its inhibitors in Alzheimer's disease murine models. Antioxidants Basel. 2021;10:218. doi: 10.3390/antiox10020218. [DOI] [PMC free article] [PubMed] [Google Scholar]
178.Harland M, Torres S, Liu J, Wang X. Neuronal mitochondria modulation of LPS-induced neuroinflammation. J Neurosci. 2020;40:1756–1765. doi: 10.1523/JNEUROSCI.2324-19.2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
179.Khan MS, Muhammad T, Ikram M, Kim MO. Dietary supplementation of the antioxidant curcumin halts systemic LPS-induced neuroinflammation-associated neurodegeneration and memory/synaptic impairment via the JNK/NF-kappaB/Akt signaling pathway in adult rats. Oxid Med Cell Longev. 2019;2019:7860650. doi: 10.1155/2019/7860650. [DOI] [PMC free article] [PubMed] [Google Scholar]
180.Li Y, Zhang L, Tang J, Yang X, Huang J, Zhu T, et al. Role of toll-like receptor 4 in the regulation of the cell death pathway and neuroinflammation. Brain Res Bull. 2019;148:79–90. doi: 10.1016/j.brainresbull.2019.03.015. [DOI] [PubMed] [Google Scholar]
181.Yang Y, Wang H, Kouadir M, Song H, Shi F. Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors. Cell Death Dis. 2019;10:1–11. doi: 10.1038/s41419-019-1413-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
182.Calvo-Rodriguez M, García-Rodríguez C, Villalobos C, Núñez L. Role of toll like receptor 4 in Alzheimer’s disease. Front Immunol. 2020;11:1588. doi: 10.3389/fimmu.2020.01588. [DOI] [PMC free article] [PubMed] [Google Scholar]
183.Mattson M, Meffert M. Roles for NF-κB in nerve cell survival, plasticity, and disease. Cell Death Differ. 2006;13:852–860. doi: 10.1038/sj.cdd.4401837. [DOI] [PubMed] [Google Scholar]
184.Angelucci F, Cechova K, Amlerova J, Hort J. Antibiotics, gut microbiota, and Alzheimer’s disease. J Neuroinflammation. 2019;16:1–10. doi: 10.1186/s12974-019-1494-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
185.Wang T, Hu X, Liang S, Li W, Wu X, Wang L, et al. Lactobacillus fermentum NS9 restores the antibiotic induced physiological and psychological abnormalities in rats. Benef Microbes. 2015;6:707–717. doi: 10.3920/BM2014.0177. [DOI] [PubMed] [Google Scholar]
186.Ribeiro CFA, Silveira G, Candido ES, Cardoso MH, Espinola Carvalho CM, Franco OL. Effects of antibiotic treatment on gut microbiota and how to overcome its negative impacts on human health. ACS Infect Dis. 2020;6:2544–2559. doi: 10.1021/acsinfecdis.0c00036. [DOI] [PubMed] [Google Scholar]
187.Balducci C, Santamaria G, La Vitola P, Brandi E, Grandi F, Viscomi AR, Beeg M, Gobbi M, Salmona M, Ottonello S, Forloni G. Doxycycline counteracts neuroinflammation restoring memory in Alzheimer's disease mouse models. Neurobiol Aging. 2018;70:128–139. doi: 10.1016/j.neurobiolaging.2018.06.002. [DOI] [PubMed] [Google Scholar]
188.Minter MR, Zhang C, Leone V, Ringus DL, Zhang X, Oyler-Castrillo P, Musch MW, Liao F, Ward JF, Holtzman DM, et al. Antibiotic-induced perturbations in gut microbial diversity influences neuro-inflammation and amyloidosis in a murine model of Alzheimer's disease. Sci Rep. 2016;6:30028. doi: 10.1038/srep30028. [DOI] [PMC free article] [PubMed] [Google Scholar]
189.Loeb MB, Molloy DW, Smieja M, Standish T, Goldsmith CH, Mahony J, Smith S, Borrie M, Decoteau E, Davidson W, et al. A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer's disease. J Am Geriatr Soc. 2004;52:381–387. doi: 10.1111/j.1532-5415.2004.52109.x. [DOI] [PubMed] [Google Scholar]
190.Rezaei Asl Z, Sepehri G, Salami M. Probiotic treatment improves the impaired spatial cognitive performance and restores synaptic plasticity in an animal model of Alzheimer's disease. Behav Brain Res. 2019;376:112183. doi: 10.1016/j.bbr.2019.112183. [DOI] [PubMed] [Google Scholar]
191.Abraham D, Feher J, Scuderi GL, Szabo D, Dobolyi A, Cservenak M, Juhasz J, Ligeti B, Pongor S, Gomez-Cabrera MC, et al. Exercise and probiotics attenuate the development of Alzheimer's disease in transgenic mice: role of microbiome. Exp Gerontol. 2019;115:122–131. doi: 10.1016/j.exger.2018.12.005. [DOI] [PubMed] [Google Scholar]
192.Nimgampalle M, Kuna Y. Anti-Alzheimer properties of probiotic, Lactobacillus plantarum MTCC 1325 in Alzheimer’s disease induced albino rats. J. Clin. Diagn. Res. JCDR. 2017;11:KC01. doi: 10.7860/JCDR/2017/26106.10428. [DOI] [PMC free article] [PubMed] [Google Scholar]
193.Akbari E, Asemi Z, Daneshvar Kakhaki R, Bahmani F, Kouchaki E, Tamtaji OR, Hamidi GA, Salami M. Effect of probiotic supplementation on cognitive function and metabolic status in Alzheimer's disease: a randomized, double-blind and controlled trial. Front Aging Neurosci. 2016;8:256. doi: 10.3389/fnagi.2016.00256. [DOI] [PMC free article] [PubMed] [Google Scholar]
194.Leblhuber F, Steiner K, Schuetz B, Fuchs D, Gostner JM. Probiotic supplementation in patients with Alzheimer's dementia-an explorative intervention study. Curr Alzheimer Res. 2018;15:1106–1113. doi: 10.2174/1389200219666180813144834. [DOI] [PMC free article] [PubMed] [Google Scholar]
195.Tamtaji OR, Heidari-Soureshjani R, Mirhosseini N, Kouchaki E, Bahmani F, Aghadavod E, Tajabadi-Ebrahimi M, Asemi Z. Probiotic and selenium co-supplementation, and the effects on clinical, metabolic and genetic status in Alzheimer's disease: a randomized, double-blind, controlled trial. Clin Nutr. 2019;38:2569–2575. doi: 10.1016/j.clnu.2018.11.034. [DOI] [PubMed] [Google Scholar]
196.Agahi A, Hamidi GA, Daneshvar R, Hamdieh M, Soheili M, Alinaghipour A, Esmaeili Taba SM, Salami M. Does severity of Alzheimer's disease contribute to its responsiveness to modifying gut microbiota? A double blind clinical trial. Front Neurol. 2018;9:662. doi: 10.3389/fneur.2018.00662. [DOI] [PMC free article] [PubMed] [Google Scholar]
197.Nagpal R, Neth BJ, Wang S, Mishra SP, Craft S, Yadav H. Gut mycobiome and its interaction with diet, gut bacteria and alzheimer's disease markers in subjects with mild cognitive impairment: A pilot study. EBioMedicine. 2020;59:102950. doi: 10.1016/j.ebiom.2020.102950. [DOI] [PMC free article] [PubMed] [Google Scholar]
198.Sun ZZ, Li XY, Wang S, Shen L, Ji HF. Bidirectional interactions between curcumin and gut microbiota in transgenic mice with Alzheimer's disease. Appl Microbiol Biotechnol. 2020;104:3507–3515. doi: 10.1007/s00253-020-10461-x. [DOI] [PubMed] [Google Scholar]
199.Park S, Kang S, Sol Kim D. Folate and vitamin B-12 deficiencies additively impaired memory function and disturbed the gut microbiota in amyloid-beta infused rats. Int J Vitam Nutr Res. 2019;1–13. [DOI] [PubMed]
200.Guo Y, Wang L, Lu J, Jiao J, Yang Y, Zhao H, et al. Ginsenoside Rg1 improves cognitive capability and affects the microbiota of large intestine of tree shrew model for Alzheimer's disease. Mol Med Rep. 2021;23:291. doi: 10.3892/mmr.2021.11931. [DOI] [PMC free article] [PubMed] [Google Scholar]
201.Bonfili L, Cecarini V, Berardi S, Scarpona S, Suchodolski JS, Nasuti C, et al. Microbiota modulation counteracts Alzheimer’s disease progression influencing neuronal proteolysis and gut hormones plasma levels. Sci Rep. 2017;7:1–21. doi: 10.1038/s41598-017-02587-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
202.Kim MS, Kim Y, Choi H, Kim W, Park S, Lee D, Kim DK, Kim HJ, Choi H, Hyun DW, et al. Transfer of a healthy microbiota reduces amyloid and tau pathology in an Alzheimer's disease animal model. Gut. 2020;69:283–294. doi: 10.1136/gutjnl-2018-317431. [DOI] [PubMed] [Google Scholar]
203.Hazan S. Rapid improvement in Alzheimer's disease symptoms following fecal microbiota transplantation: a case report. J Int Med Res. 2020;48:300060520925930. doi: 10.1177/0300060520925930. [DOI] [PMC free article] [PubMed] [Google Scholar]
204.Dominy SS, Lynch C, Ermini F, Benedyk M, Marczyk A, Konradi A, Nguyen M, Haditsch U, Raha D, Griffin C. Porphyromonas gingivalis in Alzheimer’s disease brains: evidence for disease causation and treatment with small-molecule inhibitors. Sci. Adv. 2019;5:eaau3333. doi: 10.1126/sciadv.aau3333. [DOI] [PMC free article] [PubMed] [Google Scholar]
205.Wang H, Lee IS, Braun C, Enck P. Effect of probiotics on central nervous system functions in animals and humans: a systematic review. J Neurogastroenterol Motil. 2016;22:589–605. doi: 10.5056/jnm16018. [DOI] [PMC free article] [PubMed] [Google Scholar]
206.Wang T, Hu X, Liang S, Li W, Wu X, Wang L, Jin F. Lactobacillus fermentum NS9 restores the antibiotic induced physiological and psychological abnormalities in rats. Benef Microbes. 2015;6:707–717. doi: 10.3920/BM2014.0177. [DOI] [PubMed] [Google Scholar]
207.Chen D, Yang X, Yang J, Lai G, Yong T, Tang X, Shuai O, Zhou G, Xie Y, Wu Q. Prebiotic effect of fructooligosaccharides from Morinda officinalis on Alzheimer’s disease in rodent models by targeting the microbiota-gut-brain axis. Front. Aging Neurosci. 2017;9:403. doi: 10.3389/fnagi.2017.00403. [DOI] [PMC free article] [PubMed] [Google Scholar]
208.D'Argenio V, Sarnataro D. Microbiome influence in the pathogenesis of prion and Alzheimer's diseases. Int J Mol Sci. 2019;20:4704. doi: 10.3390/ijms20194704. [DOI] [PMC free article] [PubMed] [Google Scholar]
209.Shabbir U, Arshad MS, Sameen A, Oh DH. Crosstalk between gut and brain in Alzheimer's disease: the role of gut microbiota modulation strategies. Nutrients. 2021;13:690. doi: 10.3390/nu13020690. [DOI] [PMC free article] [PubMed] [Google Scholar]
210.Willett WC, Sacks F, Trichopoulou A, Drescher G, Ferro-Luzzi A, Helsing E, Trichopoulos D. Mediterranean diet pyramid: a cultural model for healthy eating. Am J Clin Nutr. 1995;61:1402S–1406S. doi: 10.1093/ajcn/61.6.1402S. [DOI] [PubMed] [Google Scholar]
211.Nagpal R, Neth BJ, Wang S, Craft S, Yadav H. Modified Mediterranean-ketogenic diet modulates gut microbiome and short-chain fatty acids in association with Alzheimer's disease markers in subjects with mild cognitive impairment. EBioMedicine. 2019;47:529–542. doi: 10.1016/j.ebiom.2019.08.032. [DOI] [PMC free article] [PubMed] [Google Scholar]
212.Costantini L, Molinari R, Farinon B, Merendino N. Impact of omega-3 fatty acids on the gut microbiota. Int J Mol Sci. 2017;18:2645. doi: 10.3390/ijms18122645. [DOI] [PMC free article] [PubMed] [Google Scholar]
213.La Rosa F, Clerici M, Ratto D, Occhinegro A, Licito A, Romeo M, Iorio CD, Rossi P. The gut-brain axis in Alzheimer's disease and omega-3. A critical overview of clinical trials. Nutrients. 2018;10:1267. doi: 10.3390/nu10091267. [DOI] [PMC free article] [PubMed] [Google Scholar]
214.Bonfili L, Cecarini V, Berardi S, Scarpona S, Suchodolski JS, Nasuti C, Fiorini D, Boarelli MC, Rossi G, Eleuteri AM. Microbiota modulation counteracts Alzheimer's disease progression influencing neuronal proteolysis and gut hormones plasma levels. Sci Rep. 2017;7:2426. doi: 10.1038/s41598-017-02587-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
215.Kim M-S, Kim Y, Choi H, Kim W, Park S, Lee D, Kim DK, Kim HJ, Choi H, Hyun D-W. Transfer of a healthy microbiota reduces amyloid and tau pathology in an Alzheimer’s disease animal model. Gut. 2020;69:283–294. doi: 10.1136/gutjnl-2018-317431. [DOI] [PubMed] [Google Scholar]
216.Hazan S. Rapid improvement in Alzheimer’s disease symptoms following fecal microbiota transplantation: a case report. J Int Med Res. 2020;48:0300060520925930. doi: 10.1177/0300060520925930. [DOI] [PMC free article] [PubMed] [Google Scholar]
217.DeFilipp Z, Bloom PP, Torres Soto M, Mansour MK, Sater MRA, Huntley MH, Turbett S, Chung RT, Chen YB, Hohmann EL. Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant. N Engl J Med. 2019;381:2043–2050. doi: 10.1056/NEJMoa1910437. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

40035_2021_273_MOESM1_ESM.pptx^{(47.8KB, pptx)}

Data Availability Statement

Not applicable.

[CR1] 1.2020 Alzheimer's disease facts and figures. Alzheimers Dement 2020. [DOI] [PubMed]

[CR2] 2.De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV. Alzheimer's disease. Subcell Biochem. 2012;65:329–352. doi: 10.1007/978-94-007-5416-4_14. [DOI] [PubMed] [Google Scholar]

[CR3] 3.Jack CR, Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14:535–562. doi: 10.1016/j.jalz.2018.02.018. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR4] 4.Mehta D, Jackson R, Paul G, Shi J, Sabbagh M. Why do trials for Alzheimer's disease drugs keep failing? A discontinued drug perspective for 2010–2015. Expert Opin Investig Drugs. 2017;26:735–739. doi: 10.1080/13543784.2017.1323868. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR5] 5.Mawanda F, Wallace R. Can infections cause Alzheimer's disease? Epidemiol Rev. 2013;35:161–180. doi: 10.1093/epirev/mxs007. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR6] 6.Abbott A. Are infections seeding some cases of Alzheimer's disease? Nature. 2020;587:22–25. doi: 10.1038/d41586-020-03084-9. [DOI] [PubMed] [Google Scholar]

[CR7] 7.Sochocka M, Zwolinska K, Leszek J. The infectious etiology of Alzheimer's disease. Curr Neuropharmacol. 2017;15:996–1009. doi: 10.2174/1570159X15666170313122937. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR8] 8.Kim SH, Noh MY, Kim HJ, Oh KW, Park J, Lee S, et al. A therapeutic strategy for Alzheimer's disease focused on immune-inflammatory modulation. Dement Neurocogn Disord. 2019;18:33–46. doi: 10.12779/dnd.2019.18.2.33. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR9] 9.Vogt NM, Kerby RL, Dill-McFarland KA, Harding SJ, Merluzzi AP, Johnson SC, et al. Gut microbiome alterations in Alzheimer's disease. Sci Rep. 2017;7:13537. doi: 10.1038/s41598-017-13601-y. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR10] 10.Wang X, Sun G, Feng T, Zhang J, Huang X, Wang T, et al. Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer's disease progression. Cell Res. 2019;29:787–803. doi: 10.1038/s41422-019-0216-x. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR11] 11.Pritchard AB, Crean S, Olsen I, Singhrao SK. Periodontitis, microbiomes and their role in Alzheimer's disease. Front Aging Neurosci. 2017;9:336. doi: 10.3389/fnagi.2017.00336. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR12] 12.Giau VV, Wu SY, Jamerlan A, An SSA, Kim SY, Hulme J. Gut microbiota and their neuroinflammatory implications in Alzheimer's disease. Nutrients. 2018;10:1765. doi: 10.3390/nu10111765. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR13] 13.Emery DC, Shoemark DK, Batstone TE, Waterfall CM, Coghill JA, Cerajewska TL, et al. 16S rRNA next generation sequencing analysis shows bacteria in Alzheimer's post-mortem brain. Front Aging Neurosci. 2017;9:195. doi: 10.3389/fnagi.2017.00195. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR14] 14.Jiang C, Li G, Huang P, Liu Z, Zhao B. The gut microbiota and Alzheimer's disease. J Alzheimers Dis. 2017;58:1–15. doi: 10.3233/JAD-161141. [DOI] [PubMed] [Google Scholar]

[CR15] 15.Zhan X, Stamova B, Jin LW, DeCarli C, Phinney B, Sharp FR. Gram-negative bacterial molecules associate with Alzheimer disease pathology. Neurology. 2016;87:2324–2332. doi: 10.1212/WNL.0000000000003391. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR16] 16.Pretorius E, Bester J, Kell DB. A bacterial component to Alzheimer's-type dementia seen via a systems biology approach that links iron dysregulation and inflammagen shedding to disease. J Alzheimers Dis. 2016;53:1237–1256. doi: 10.3233/JAD-160318. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR17] 17.Fulop T, Witkowski JM, Bourgade K, Khalil A, Zerif E, Larbi A, et al. Can an infection hypothesis explain the beta amyloid hypothesis of Alzheimer's disease? Front Aging Neurosci. 2018;10:224. doi: 10.3389/fnagi.2018.00224. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR18] 18.Brown GC. The endotoxin hypothesis of neurodegeneration. J Neuroinflammation. 2019;16:180. doi: 10.1186/s12974-019-1564-7. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR19] 19.Hung YL, Fang SH, Wang SC, Cheng WC, Liu PL, Su CC, et al. Corylin protects LPS-induced sepsis and attenuates LPS-induced inflammatory response. Sci Rep. 2017;7:46299. doi: 10.1038/srep46299. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR20] 20.Chou CH, Lee JT, Lin CC, Sung YF, Lin CC, Muo CH, et al. Septicemia is associated with increased risk for dementia: a population-based longitudinal study. Oncotarget. 2017;8:84300–84308. doi: 10.18632/oncotarget.20899. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR21] 21.Iwashyna TJ, Ely EW, Smith DM, Langa KM. Long-term cognitive impairment and functional disability among survivors of severe sepsis. JAMA. 2010;304:1787–1794. doi: 10.1001/jama.2010.1553. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR22] 22.Zhang R, Miller RG, Gascon R, Champion S, Katz J, Lancero M, et al. Circulating endotoxin and systemic immune activation in sporadic amyotrophic lateral sclerosis (sALS) J Neuroimmunol. 2009;206:121–124. doi: 10.1016/j.jneuroim.2008.09.017. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR23] 23.Lee HJ, Lee KE, Kim JK, Kim DH. Suppression of gut dysbiosis by Bifidobacterium longum alleviates cognitive decline in 5XFAD transgenic and aged mice. Sci Rep. 2019;9:11814. doi: 10.1038/s41598-019-48342-7. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR24] 24.Zhan X, Stamova B, Sharp FR. Lipopolysaccharide associates with amyloid plaques, neurons and oligodendrocytes in Alzheimer's disease brain: a review. Front Aging Neurosci. 2018;10:42. doi: 10.3389/fnagi.2018.00042. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR25] 25.Honjo K, van Reekum R, Verhoeff NP. Alzheimer's disease and infection: do infectious agents contribute to progression of Alzheimer's disease? Alzheimers Dement. 2009;5:348–360. doi: 10.1016/j.jalz.2008.12.001. [DOI] [PubMed] [Google Scholar]

[CR26] 26.Beydoun MA, Beydoun HA, Weiss J, Hossain S, El-Hajj ZW, Zonderman AB. Helicobacter pylori, periodontal pathogens, and their interactive association with incident all-cause and Alzheimer's disease dementia in a large national survey. Mol Psychiatry 2020. [DOI] [PubMed]

[CR27] 27.Beydoun MA, Beydoun HA, Hossain S, El-Hajj ZW, Weiss J, Zonderman AB. Clinical and bacterial markers of periodontitis and their association with incident all-cause and Alzheimer's disease dementia in a large national survey. J Alzheimers Dis. 2020;75:157–172. doi: 10.3233/JAD-200064. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR28] 28.Park J, Kim TJ, Song JH, Jang H, Kim JS, Kang SH, et al. Helicobacter pylori infection is associated with neurodegeneration in cognitively normal men. J Alzheimers Dis. 2021;82:1591–1599. doi: 10.3233/JAD-210119. [DOI] [PubMed] [Google Scholar]

[CR29] 29.Zilli EM, O'Donnell A, Salinas J, Aparicio HJ, Gonzales MM, Jacob M, Beiser A, et al. Herpes Labialis, Chlamydophila pneumoniae, Helicobacter pylori, and cytomegalovirus infections and risk of dementia: the framingham heart study. J Alzheimers Dis. 2021;82:593–605. doi: 10.3233/JAD-200957. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR30] 30.Fu P, Gao M, Yung KKL. Association of intestinal disorders with Parkinson's disease and Alzheimer's disease: a systematic review and meta-analysis. ACS Chem Neurosci. 2020;11:395–405. doi: 10.1021/acschemneuro.9b00607. [DOI] [PubMed] [Google Scholar]

[CR31] 31.Beydoun MA, Beydoun HA, Elbejjani M, Dore GA, Zonderman AB. Helicobacter pylori seropositivity and its association with incident all-cause and Alzheimer's disease dementia in large national surveys. Alzheimers Dement. 2018;14:1148–1158. doi: 10.1016/j.jalz.2018.04.009. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR32] 32.Harach T, Marungruang N, Duthilleul N, Cheatham V, Mc Coy KD, Frisoni G, et al. Reduction of Abeta amyloid pathology in APPPS1 transgenic mice in the absence of gut microbiota. Sci Rep. 2017;7:41802. doi: 10.1038/srep41802. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR33] 33.Shen L, Liu L, Ji H-F. Alzheimer’s disease histological and behavioral manifestations in transgenic mice correlate with specific gut microbiome state. J Alzheimers Dis. 2017;56:385–390. doi: 10.3233/JAD-160884. [DOI] [PubMed] [Google Scholar]

[CR34] 34.Bauerl C, Collado MC, Diaz Cuevas A, Vina J, Perez Martinez G. Shifts in gut microbiota composition in an APP/PSS1 transgenic mouse model of Alzheimer's disease during lifespan. Lett Appl Microbiol. 2018;66:464–471. doi: 10.1111/lam.12882. [DOI] [PubMed] [Google Scholar]

[CR35] 35.Brandscheid C, Schuck F, Reinhardt S, Schafer KH, Pietrzik CU, Grimm M, et al. Altered gut microbiome composition and tryptic activity of the 5xFAD Alzheimer's mouse model. J Alzheimers Dis. 2017;56:775–788. doi: 10.3233/JAD-160926. [DOI] [PubMed] [Google Scholar]

[CR36] 36.MacIntyre A, Abramov R, Hammond CJ, Hudson AP, Arking EJ, Little CS, et al. Chlamydia pneumoniae infection promotes the transmigration of monocytes through human brain endothelial cells. J Neurosci Res. 2003;71:740–750. doi: 10.1002/jnr.10519. [DOI] [PubMed] [Google Scholar]

[CR37] 37.Arking EJ, Appelt DM, Abrams JT, Kolbe S, Hudson AP, Balin BJ. Ultrastructural analysis of Chlamydia pneumoniae in the Alzheimer's brain. Pathogenesis (Amst) 1999;1:201–211. [PMC free article] [PubMed] [Google Scholar]

[CR38] 38.Poole S, Singhrao SK, Kesavalu L, Curtis MA, Crean S. Determining the presence of periodontopathic virulence factors in short-term postmortem Alzheimer's disease brain tissue. J Alzheimers Dis. 2013;36:665–677. doi: 10.3233/JAD-121918. [DOI] [PubMed] [Google Scholar]

[CR39] 39.Huma Siddiqui ERE, Singhrao SK, Olsen I. High throughput sequencing detect gingivitis and periodontal oral bacteria in Alzheimer’s disease autopsy brains. Neuro Res. 2019;1:3. [Google Scholar]

[CR40] 40.Balin BJ, Gerard HC, Arking EJ, Appelt DM, Branigan PJ, Abrams JT, Whittum-Hudson JA, Hudson AP. Identification and localization of Chlamydia pneumoniae in the Alzheimer's brain. Med Microbiol Immunol. 1998;187:23–42. doi: 10.1007/s004300050071. [DOI] [PubMed] [Google Scholar]

[CR41] 41.Gerard HC, Dreses-Werringloer U, Wildt KS, Deka S, Oszust C, Balin BJ. Chlamydophila (Chlamydia) pneumoniae in the Alzheimer's brain. FEMS Immunol Med Microbiol. 2006;48:355–366. doi: 10.1111/j.1574-695X.2006.00154.x. [DOI] [PubMed] [Google Scholar]

[CR42] 42.Riviere GR, Riviere KH, Smith KS. Molecular and immunological evidence of oral Treponema in the human brain and their association with Alzheimer's disease. Oral Microbiol Immunol. 2002;17:113–118. doi: 10.1046/j.0902-0055.2001.00100.x. [DOI] [PubMed] [Google Scholar]

[CR43] 43.Gerard HC, Wildt KL, Whittum-Hudson JA, Lai Z, Ager J, Hudson AP. The load of Chlamydia pneumoniae in the Alzheimer's brain varies with APOE genotype. Microb Pathog. 2005;39:19–26. doi: 10.1016/j.micpath.2005.05.002. [DOI] [PubMed] [Google Scholar]

[CR44] 44.Miklossy J, Kasas S, Janzer RC, Ardizzoni F, Van der Loos H. Further ultrastructural evidence that spirochaetes may play a role in the aetiology of Alzheimer's disease. NeuroReport. 1994;5:1201–1204. doi: 10.1097/00001756-199406020-00010. [DOI] [PubMed] [Google Scholar]

[CR45] 45.Dreses-Werringloer U, Bhuiyan M, Zhao Y, Gerard HC, Whittum-Hudson JA, Hudson AP. Initial characterization of Chlamydophila (Chlamydia) pneumoniae cultured from the late-onset Alzheimer brain. Int J Med Microbiol. 2009;299:187–201. doi: 10.1016/j.ijmm.2008.07.002. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR46] 46.Miklossy J, Khalili K, Gern L, Ericson RL, Darekar P, Bolle L, et al. Borrelia burgdorferi persists in the brain in chronic lyme neuroborreliosis and may be associated with Alzheimer disease. J Alzheimers Dis. 2004;6:639–649. doi: 10.3233/jad-2004-6608. [DOI] [PubMed] [Google Scholar]

[CR47] 47.Paradowski B, Jaremko M, Dobosz T, Leszek J, Noga L. Evaluation of CSF-Chlamydia pneumoniae, CSF-tau, and CSF-Abeta42 in Alzheimer's disease and vascular dementia. J Neurol. 2007;254:154–159. doi: 10.1007/s00415-006-0298-5. [DOI] [PubMed] [Google Scholar]

[CR48] 48.Kountouras J, Boziki M, Gavalas E, Zavos C, Deretzi G, Grigoriadis N, et al. Increased cerebrospinal fluid Helicobacter pylori antibody in Alzheimer's disease. Int J Neurosci. 2009;119:765–777. doi: 10.1080/00207450902782083. [DOI] [PubMed] [Google Scholar]

[CR49] 49.Miklossy J. Alzheimer's disease–a spirochetosis? NeuroReport. 1993;4:841–848. [PubMed] [Google Scholar]

[CR50] 50.Zhang L, Wang Y, Xiayu X, Shi C, Chen W, Song N, et al. Altered gut microbiota in a mouse model of Alzheimer's disease. J Alzheimers Dis. 2017;60:1241–1257. doi: 10.3233/JAD-170020. [DOI] [PubMed] [Google Scholar]

[CR51] 51.Chen C, Ahn EH, Kang SS, Liu X, Alam A, Ye K. Gut dysbiosis contributes to amyloid pathology, associated with C/EBPbeta/AEP signaling activation in Alzheimer's disease mouse model. Sci Adv. 2020;6:eaba0466. doi: 10.1126/sciadv.aba0466. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR52] 52.Bu XL, Yao XQ, Jiao SS, Zeng F, Liu YH, Xiang Y, et al. A study on the association between infectious burden and Alzheimer's disease. Eur J Neurol. 2015;22:1519–1525. doi: 10.1111/ene.12477. [DOI] [PubMed] [Google Scholar]

[CR53] 53.Herrera-Landero A, Amaya-Sánchez LE, De Las-Deses CD, Solórzano-Santos F, Gordillo-Pérez MG. Borrelia burgdorferi as a risk factor for Alzheimer’s dementia and mild cognitive impairment. European Geriatric Medicine. 2019;10:493–500. doi: 10.1007/s41999-018-0153-0. [DOI] [PubMed] [Google Scholar]

[CR54] 54.Al-Obaidi MMJ, Desa MNM. Mechanisms of blood brain barrier disruption by different types of bacteria, and bacterial-host interactions facilitate the bacterial pathogen invading the brain. Cell Mol Neurobiol. 2018;38:1349–1368. doi: 10.1007/s10571-018-0609-2. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR55] 55.Zhou Y, Tao J, Yu H, Ni J, Zeng L, Teng Q, et al. Hcp family proteins secreted via the type VI secretion system coordinately regulate Escherichia coli K1 interaction with human brain microvascular endothelial cells. Infect Immun. 2012;80:1243–1251. doi: 10.1128/IAI.05994-11. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR56] 56.Mittal R, Prasadarao NV. Nitric oxide/cGMP signalling induces Escherichia coli K1 receptor expression and modulates the permeability in human brain endothelial cell monolayers during invasion. Cell Microbiol. 2010;12:67–83. doi: 10.1111/j.1462-5822.2009.01379.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR57] 57.Kristensson K. Microbes' roadmap to neurons. Nat Rev Neurosci. 2011;12:345–357. doi: 10.1038/nrn3029. [DOI] [PubMed] [Google Scholar]

[CR58] 58.Rodriguez Coyago ML, Sanchez Temino VE. Periodontitis determining the onset and progression of Huntington's disease: review of the literature. Medwave. 2015;15:e6293. doi: 10.5867/medwave.2015.09.6293. [DOI] [PubMed] [Google Scholar]

[CR59] 59.Dominy SS, Lynch C, Ermini F, Benedyk M, Marczyk A, Konradi A, et al. Porphyromonas gingivalis in Alzheimer's disease brains: evidence for disease causation and treatment with small-molecule inhibitors. Sci Adv. 2019;5:eaau3333. doi: 10.1126/sciadv.aau3333. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR60] 60.Poole S, Singhrao SK, Chukkapalli S, Rivera M, Velsko I, Kesavalu L, et al. Active invasion of Porphyromonas gingivalis and infection-induced complement activation in ApoE-/- mice brains. J Alzheimers Dis. 2015;43:67–80. doi: 10.3233/JAD-140315. [DOI] [PubMed] [Google Scholar]

[CR61] 61.Doulberis M, Kotronis G, Thomann R, Polyzos SA, Boziki M, Gialamprinou D, et al. Review: impact of Helicobacter pylori on Alzheimer's disease: what do we know so far? Helicobacter. 2018;23:12454. doi: 10.1111/hel.12454. [DOI] [PubMed] [Google Scholar]

[CR62] 62.Strandwitz P. Neurotransmitter modulation by the gut microbiota. Brain Res. 2018;1693:128–133. doi: 10.1016/j.brainres.2018.03.015. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR63] 63.Carabotti M, Scirocco A, Maselli MA, Severi C. The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. Ann Gastroenterol. 2015;28:203–209. [PMC free article] [PubMed] [Google Scholar]

[CR64] 64.Ma Q, Xing C, Long W, Wang HY, Liu Q, Wang RF. Impact of microbiota on central nervous system and neurological diseases: the gut-brain axis. J Neuroinflammation. 2019;16:53. doi: 10.1186/s12974-019-1434-3. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR65] 65.Liu S, Gao J, Zhu M, Liu K, Zhang HL. Gut microbiota and dysbiosis in Alzheimer's disease: implications for pathogenesis and treatment. Mol Neurobiol. 2020;57:5026–5043. doi: 10.1007/s12035-020-02073-3. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR66] 66.Hill JM, Clement C, Pogue AI, Bhattacharjee S, Zhao Y, Lukiw WJ. Pathogenic microbes, the microbiome, and Alzheimer's disease (AD) Front Aging Neurosci. 2014;6:127. doi: 10.3389/fnagi.2014.00127. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR67] 67.Honarpisheh P, Reynolds CR, Blasco Conesa MP, Moruno Manchon JF, Putluri N, Bhattacharjee MB, Urayama A, McCullough LD, Ganesh BP. Dysregulated Gut Homeostasis Observed Prior to the Accumulation of the Brain Amyloid-beta in Tg2576 Mice. Int J Mol Sci. 2020;21:1711. doi: 10.3390/ijms21051711. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR68] 68.Schwartz K, Boles BR. Microbial amyloids–functions and interactions within the host. Curr Opin Microbiol. 2013;16:93–99. doi: 10.1016/j.mib.2012.12.001. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR69] 69.Javed I, Zhang Z, Adamcik J, Andrikopoulos N, Li Y, Otzen DE, et al. Accelerated amyloid beta pathogenesis by bacterial amyloid FapC. Adv Sci. 2020;7:2001299. doi: 10.1002/advs.202001299. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR70] 70.Shewmaker F, McGlinchey RP, Thurber KR, McPhie P, Dyda F, Tycko R, et al. The functional curli amyloid is not based on in-register parallel beta-sheet structure. J Biol Chem. 2009;284:25065–25076. doi: 10.1074/jbc.M109.007054. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR71] 71.Hill JM, Lukiw WJ. Microbial-generated amyloids and Alzheimer's disease (AD) Front Aging Neurosci. 2015;7:9. doi: 10.3389/fnagi.2015.00009. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR72] 72.Chapman MR, Robinson LS, Pinkner JS, Roth R, Heuser J, Hammar M, et al. Role of Escherichia coli curli operons in directing amyloid fiber formation. Science. 2002;295:851–855. doi: 10.1126/science.1067484. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR73] 73.Zhao Y, Dua P, Lukiw WJ. Microbial sources of amyloid and relevance to amyloidogenesis and Alzheimer's disease (AD) J Alzheimers Dis Parkinsonism. 2015;5:177. doi: 10.4172/2161-0460.1000177. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR74] 74.Friedland RP, Chapman MR. The role of microbial amyloid in neurodegeneration. PLOS Pathog. 2017;13:e1006654. doi: 10.1371/journal.ppat.1006654. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR75] 75.Oskarsson ME, Paulsson JF, Schultz SW, Ingelsson M, Westermark P, Westermark GT. In vivo seeding and cross-seeding of localized amyloidosis: a molecular link between type 2 diabetes and Alzheimer disease. Am J Pathol. 2015;185:834–846. doi: 10.1016/j.ajpath.2014.11.016. [DOI] [PubMed] [Google Scholar]

[CR76] 76.Moreno-Gonzalez I, Edwards Iii G, Salvadores N, Shahnawaz M, Diaz-Espinoza R, Soto C. Molecular interaction between type 2 diabetes and Alzheimer's disease through cross-seeding of protein misfolding. Mol Psychiatry. 2017;22:1327–1334. doi: 10.1038/mp.2016.230. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR77] 77.Cherny I, Rockah L, Levy-Nissenbaum O, Gophna U, Ron EZ, Gazit E. The formation of Escherichia coli curli amyloid fibrils is mediated by prion-like peptide repeats. J Mol Biol. 2005;352:245–252. doi: 10.1016/j.jmb.2005.07.028. [DOI] [PubMed] [Google Scholar]

[CR78] 78.Yan Z, Yin M, Chen J, Li X. Assembly and substrate recognition of curli biogenesis system. Nat Commun. 2020;11:241. doi: 10.1038/s41467-019-14145-7. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR79] 79.Van Gerven N, Klein RD, Hultgren SJ, Remaut H. Bacterial amyloid formation: structural insights into curli biogensis. Trends Microbiol. 2015;23:693–706. doi: 10.1016/j.tim.2015.07.010. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR80] 80.Shu Q, Crick SL, Pinkner JS, Ford B, Hultgren SJ, Frieden C. The E. coli CsgB nucleator of curli assembles to beta-sheet oligomers that alter the CsgA fibrillization mechanism. Proc Natl Acad Sci USA. 2012;109:6502–6507. doi: 10.1073/pnas.1204161109. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR81] 81.Dueholm MS, Petersen SV, Sonderkaer M, Larsen P, Christiansen G, Hein KL, et al. Functional amyloid in pseudomonas. Mol Microbiol. 2010;77:1009–1020. doi: 10.1111/j.1365-2958.2010.07269.x. [DOI] [PubMed] [Google Scholar]

[CR82] 82.Javed I, Zhang Z, Adamcik J, Andrikopoulos N, Li Y, Otzen DE, et al. Accelerated amyloid beta pathogenesis by bacterial amyloid FapC. Adv Sci (Weinh) 2020;7:2001299. doi: 10.1002/advs.202001299. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR83] 83.Rapsinski GJ, Newman TN, Oppong GO, van Putten JP, Tukel C. CD14 protein acts as an adaptor molecule for the immune recognition of Salmonella curli fibers. J Biol Chem. 2013;288:14178–14188. doi: 10.1074/jbc.M112.447060. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR84] 84.Shin MG, Lee JW, Han JS, Lee B, Jeong JH, Park SH, et al. Bacteria-derived metabolite, methylglyoxal, modulates the longevity of C. elegans through TORC2/SGK-1/DAF-16 signaling. Proc Natl Acad Sci USA. 2020;117:17142–17150. doi: 10.1073/pnas.1915719117. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR85] 85.Krautwald M, Munch G. Advanced glycation end products as biomarkers and gerontotoxins: a basis to explore methylglyoxal-lowering agents for Alzheimer's disease? Exp Gerontol. 2010;45:744–751. doi: 10.1016/j.exger.2010.03.001. [DOI] [PubMed] [Google Scholar]

[CR86] 86.Cho HJ, Son SM, Jin SM, Hong HS, Shin DH, Kim SJ, et al. RAGE regulates BACE1 and Abeta generation via NFAT1 activation in Alzheimer's disease animal model. FASEB J. 2009;23:2639–2649. doi: 10.1096/fj.08-126383. [DOI] [PubMed] [Google Scholar]

[CR87] 87.Ilievski V, Zuchowska PK, Green SJ, Toth PT, Ragozzino ME, Le K, et al. Chronic oral application of a periodontal pathogen results in brain inflammation, neurodegeneration and amyloid beta production in wild type mice. PLOS One. 2018;13:e0204941. doi: 10.1371/journal.pone.0204941. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR88] 88.Armbrust F, Colmorgen C, Pietrzik CU, Becker-Pauly C. The Alzheimer’s disease associated bacterial protease RgpB from P. gingivalis activates the alternative β-secretase meprin β thereby increasing Aβ generation. bioRxiv 2019;748814. 10.1101/748814

[CR89] 89.Li XH, Xie JZ, Jiang X, Lv BL, Cheng XS, Du LL, et al. Methylglyoxal induces tau hyperphosphorylation via promoting AGEs formation. Neuromol Med. 2012;14:338–348. doi: 10.1007/s12017-012-8191-0. [DOI] [PubMed] [Google Scholar]

[CR90] 90.Cadamuro AC, Rossi AF, Maniezzo NM, Silva AE. Helicobacter pylori infection: host immune response, implications on gene expression and microRNAs. World J Gastroenterol. 2014;20:1424–1437. doi: 10.3748/wjg.v20.i6.1424. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR91] 91.de Bernard M, Moschioni M, Papini E, Telford J, Rappuoli R, Montecucco C. Cell vacuolization induced by Helicobacter pylori VacA toxin: cell line sensitivity and quantitative estimation. Toxicol Lett. 1998;99:109–115. doi: 10.1016/s0378-4274(98)00140-4. [DOI] [PubMed] [Google Scholar]

[CR92] 92.Kumar H, Jo MJ, Choi H, Muttigi MS, Shon S, Kim BJ, et al. Matrix metalloproteinase-8 inhibition prevents disruption of blood-spinal cord barrier and attenuates inflammation in rat model of spinal cord injury. Mol Neurobiol. 2018;55:2577–2590. doi: 10.1007/s12035-017-0509-3. [DOI] [PubMed] [Google Scholar]

[CR93] 93.Blank M, Bashi T, Lachnish J, Ben-Ami-Shor D, Shovman O, Fridkin M, et al. Helminths-based bi-functional molecule, tuftsin-phosphorylcholine (TPC), ameliorates an established murine arthritis. PLOS ONE. 2018;13:e0200615. doi: 10.1371/journal.pone.0200615. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR94] 94.Erny D, de Angelis ALH, Jaitin D, Wieghofer P, Staszewski O, David E, et al. Host microbiota constantly control maturation and function of microglia in the CNS. Nat Neurosci. 2015;18:965–977. doi: 10.1038/nn.4030. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR95] 95.Colombo AV, Sadler RK, Llovera G, Singh V, Roth S, Heindl S, et al. Microbiota-derived short chain fatty acids modulate microglia and promote Aβ plaque deposition. eLife. 2021;10:e59826. doi: 10.7554/eLife.59826. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR96] 96.Marizzoni M, Cattaneo A, Mirabelli P, Festari C, Lopizzo N, Nicolosi V, et al. Short-chain fatty acids and lipopolysaccharide as mediators between gut dysbiosis and amyloid pathology in Alzheimer's disease. J Alzheimers Dis. 2020;78(2):683–697. doi: 10.3233/JAD-200306. [DOI] [PubMed] [Google Scholar]

[CR97] 97.Rothhammer V, Mascanfroni ID, Bunse L, Takenaka MC, Kenison JE, Mayo L, et al. Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor. Nat Med. 2016;22:586–597. doi: 10.1038/nm.4106. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR98] 98.Iqbal K, Liu F, Gong CX, Grundke-Iqbal I. Tau in Alzheimer disease and related tauopathies. Curr Alzheimer Res. 2010;7:656–664. doi: 10.2174/156720510793611592. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR99] 99.Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem. 1986;261:6084–6089. [PubMed] [Google Scholar]

[CR100] 100.Khlistunova I, Biernat J, Wang Y, Pickhardt M, von Bergen M, Gazova Z, et al. Inducible expression of Tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs. J Biol Chem. 2006;281:1205–1214. doi: 10.1074/jbc.M507753200. [DOI] [PubMed] [Google Scholar]

[CR101] 101.Ferrer I, Gomez-Isla T, Puig B, Freixes M, Ribe E, Dalfo E, Avila J. Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies. Curr Alzheimer Res. 2005;2:3–18. doi: 10.2174/1567205052772713. [DOI] [PubMed] [Google Scholar]

[CR102] 102.Wang XL, Zeng J, Yang Y, Xiong Y, Zhang ZH, Qiu M, Yan X, Sun XY, Tuo QZ, Liu R, Wang JZ. Helicobacter pylori filtrate induces Alzheimer-like tau hyperphosphorylation by activating glycogen synthase kinase-3beta. J Alzheimers Dis. 2015;43:153–165. doi: 10.3233/JAD-140198. [DOI] [PubMed] [Google Scholar]

[CR103] 103.Haditsch U, Roth T, Rodriguez L, Hancock S, Cecere T, Nguyen M, Arastu-Kapur S, Broce S, Raha D, Lynch CC, et al. Alzheimer's disease-like neurodegeneration in Porphyromonas gingivalis infected neurons with persistent expression of active gingipains. J Alzheimers Dis. 2020;75:1361–1376. doi: 10.3233/JAD-200393. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR104] 104.Kanagasingam S, Chukkapalli SS, Welbury R, Singhrao SK. Porphyromonas gingivalis is a strong risk factor for Alzheimer's disease. J Alzheimers Dis Rep. 2020;4:501–511. doi: 10.3233/ADR-200250. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR105] 105.Chu J, Lauretti E, Pratico D. Caspase-3-dependent cleavage of Akt modulates tau phosphorylation via GSK3beta kinase: implications for Alzheimer's disease. Mol Psychiatry. 2017;22:1002–1008. doi: 10.1038/mp.2016.214. [DOI] [PubMed] [Google Scholar]

[CR106] 106.Kovacech B, Novak M. Tau truncation is a productive posttranslational modification of neurofibrillary degeneration in Alzheimer's disease. Curr Alzheimer Res. 2010;7:708–716. doi: 10.2174/156720510793611556. [DOI] [PubMed] [Google Scholar]

[CR107] 107.Yin H, Kuret J. C-terminal truncation modulates both nucleation and extension phases of tau fibrillization. FEBS Lett. 2006;580:211–215. doi: 10.1016/j.febslet.2005.11.077. [DOI] [PubMed] [Google Scholar]

[CR108] 108.Taniguchi-Watanabe S, Arai T, Kametani F, Nonaka T, Masuda-Suzukake M, Tarutani A, et al. Biochemical classification of tauopathies by immunoblot, protein sequence and mass spectrometric analyses of sarkosyl-insoluble and trypsin-resistant tau. Acta Neuropathol. 2016;131:267–280. doi: 10.1007/s00401-015-1503-3. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR109] 109.Tetz G, Pinho M, Pritzkow S, Mendez N, Soto C, Tetz V. Bacterial DNA promotes Tau aggregation. Sci Rep. 2020;10:2369. doi: 10.1038/s41598-020-59364-x. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR110] 110.Regen F, Hellmann-Regen J, Costantini E, Reale M. Neuroinflammation and Alzheimer's disease: implications for microglial activation. Curr Alzheimer Res. 2017;14:1140–1148. doi: 10.2174/1567205014666170203141717. [DOI] [PubMed] [Google Scholar]

[CR111] 111.Kinney JW, Bemiller SM, Murtishaw AS, Leisgang AM, Salazar AM, Lamb BT. Inflammation as a central mechanism in Alzheimer's disease. Alzheimers Dement (N Y) 2018;4:575–590. doi: 10.1016/j.trci.2018.06.014. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR112] 112.Dickson K, Lehmann C. Inflammatory response to different toxins in experimental sepsis models. Int J Mol Sci. 2019;20:4341. doi: 10.3390/ijms20184341. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR113] 113.McManus RM, Higgins SC, Mills KH, Lynch MA. Respiratory infection promotes T cell infiltration and amyloid-beta deposition in APP/PS1 mice. Neurobiol Aging. 2014;35:109–121. doi: 10.1016/j.neurobiolaging.2013.07.025. [DOI] [PubMed] [Google Scholar]

[CR114] 114.Balin BJ, Hammond CJ, Little CS, Hingley ST, Al-Atrache Z, Appelt DM, et al. Chlamydia pneumoniae: an etiologic agent for late-onset dementia. Front Aging Neurosci. 2018;10:302. doi: 10.3389/fnagi.2018.00302. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR115] 115.Ikejima H, Friedman H, Yamamoto Y. Chlamydia pneumoniae infection of microglial cells in vitro: a model of microbial infection for neurological disease. J Med Microbiol. 2006;55:947–952. doi: 10.1099/jmm.0.46348-0. [DOI] [PubMed] [Google Scholar]

[CR116] 116.Tajes M, Eraso-Pichot A, Rubio-Moscardo F, Guivernau B, Ramos-Fernandez E, Bosch-Morato M, et al. Methylglyoxal produced by amyloid-beta peptide-induced nitrotyrosination of triosephosphate isomerase triggers neuronal death in Alzheimer's disease. J Alzheimers Dis. 2014;41:273–288. doi: 10.3233/JAD-131685. [DOI] [PubMed] [Google Scholar]

[CR117] 117.Tajes M, Eraso-Pichot A, Rubio-Moscardo F, Guivernau B, Bosch-Morato M, Valls-Comamala V, et al. Methylglyoxal reduces mitochondrial potential and activates Bax and caspase-3 in neurons: implications for Alzheimer's disease. Neurosci Lett. 2014;580:78–82. doi: 10.1016/j.neulet.2014.07.047. [DOI] [PubMed] [Google Scholar]

[CR118] 118.Calvo-Rodriguez M, Garcia-Rodriguez C, Villalobos C, Nunez L. Role of toll like receptor 4 in Alzheimer's disease. Front Immunol. 2020;11:1588. doi: 10.3389/fimmu.2020.01588. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR119] 119.Li Y, Zhang L, Tang J, Yang X, Huang J, Zhu T, et al. Role of toll-like receptor 4 in the regulation of the cell death pathway and neuroinflammation. Brain Res Bull. 2019;148:79–90. doi: 10.1016/j.brainresbull.2019.03.015. [DOI] [PubMed] [Google Scholar]

[CR120] 120.d'Hennezel E, Abubucker S, Murphy LO, Cullen TW. Total Lipopolysaccharide from the Human Gut Microbiome Silences Toll-Like Receptor Signaling. Msystems. 2017;2:e00046-17. doi: 10.1128/mSystems.00046-17. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR121] 121.Guo S, Al-Sadi R, Said HM, Ma TY. Lipopolysaccharide causes an increase in intestinal tight junction permeability in vitro and in vivo by inducing enterocyte membrane expression and localization of TLR-4 and CD14. Am J Pathol. 2013;182:375–387. doi: 10.1016/j.ajpath.2012.10.014. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR122] 122.Ghosh SS, Wang J, Yannie PJ, Ghosh S. Intestinal barrier dysfunction, LPS translocation, and disease development. J Endocr Soc. 2020;4:bvz039. doi: 10.1210/jendso/bvz039. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR123] 123.Zhao Y, Jaber V, Lukiw WJ. Secretory products of the human GI tract microbiome and their potential impact on Alzheimer's disease (AD): detection of lipopolysaccharide (LPS) in AD hippocampus. Front Cell Infect Microbiol. 2017;7:318. doi: 10.3389/fcimb.2017.00318. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR124] 124.Zhao Y, Cong L, Lukiw WJ. Lipopolysaccharide (LPS) accumulates in neocortical neurons of Alzheimer's disease (AD) brain and impairs transcription in human neuronal-glial primary co-cultures. Front Aging Neurosci. 2017;9:407. doi: 10.3389/fnagi.2017.00407. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR125] 125.Zhao Y, Cong L, Jaber V, Lukiw WJ. Microbiome-derived lipopolysaccharide enriched in the perinuclear region of Alzheimer's disease brain. Front Immunol. 2017;8:1064. doi: 10.3389/fimmu.2017.01064. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR126] 126.Vargas-Caraveo A, Sayd A, Maus SR, Caso JR, Madrigal JLM, Garcia-Bueno B, et al. Lipopolysaccharide enters the rat brain by a lipoprotein-mediated transport mechanism in physiological conditions. Sci Rep. 2017;7:13113. doi: 10.1038/s41598-017-13302-6. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR127] 127.Gotsch U, Jager U, Dominis M, Vestweber D. Expression of P-selectin on endothelial cells is upregulated by LPS and TNF-alpha in vivo. Cell Adhes Commun. 1994;2:7–14. doi: 10.3109/15419069409014198. [DOI] [PubMed] [Google Scholar]

[CR128] 128.Meena M, Cools N. On the road to new treatments for multiple sclerosis: targeting dendritic cell migration into the central nervous system. Neural Regen Res. 2019;14:2088–2090. doi: 10.4103/1673-5374.262583. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR129] 129.Coisne C, Dehouck L, Faveeuw C, Delplace Y, Miller F, Landry C, et al. Mouse syngenic in vitro blood-brain barrier model: a new tool to examine inflammatory events in cerebral endothelium. Lab Invest. 2005;85:734–746. doi: 10.1038/labinvest.3700281. [DOI] [PubMed] [Google Scholar]

[CR130] 130.Varatharaj A, Galea I. The blood-brain barrier in systemic inflammation. Brain Behav Immun. 2017;60:1–12. doi: 10.1016/j.bbi.2016.03.010. [DOI] [PubMed] [Google Scholar]

[CR131] 131.Nonaka N, Shioda S, Banks WA. Effect of lipopolysaccharide on the transport of pituitary adenylate cyclase activating polypeptide across the blood-brain barrier. Exp Neurol. 2005;191:137–144. doi: 10.1016/j.expneurol.2004.09.013. [DOI] [PubMed] [Google Scholar]

[CR132] 132.Woodcock TE, Woodcock TM. Revised Starling equation and the glycocalyx model of transvascular fluid exchange: an improved paradigm for prescribing intravenous fluid therapy. Br J Anaesth. 2012;108:384–394. doi: 10.1093/bja/aer515. [DOI] [PubMed] [Google Scholar]

[CR133] 133.Heinbockel L, Weindl G, Martinez-de-Tejada G, Correa W, Sanchez-Gomez S, Barcena-Varela S, et al. Inhibition of lipopolysaccharide- and lipoprotein-induced inflammation by antitoxin peptide pep19–2.5. Front Immunol. 2018;9:1704. doi: 10.3389/fimmu.2018.01704. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR134] 134.Le Guennec L, Coureuil M, Nassif X, Bourdoulous S. Strategies used by bacterial pathogens to cross the blood-brain barrier. Cell Microbiol. 2020;22:e13132. doi: 10.1111/cmi.13132. [DOI] [PubMed] [Google Scholar]

[CR135] 135.Pfalzgraff A, Correa W, Heinbockel L, Schromm AB, Lubow C, Gisch N, et al. LPS-neutralizing peptides reduce outer membrane vesicle-induced inflammatory responses. Biochim Biophys Acta Mol Cell Biol Lipids. 2019;1864:1503–1513. doi: 10.1016/j.bbalip.2019.05.018. [DOI] [PubMed] [Google Scholar]

[CR136] 136.Lee HJ, Hwang YH, Kim DH. Lactobacillus plantarum C29-fermented soybean (DW2009) alleviates memory impairment in 5XFAD transgenic mice by regulating microglia activation and gut microbiota composition. Mol Nutr Food Res. 2018;62:e1800359. doi: 10.1002/mnfr.201800359. [DOI] [PubMed] [Google Scholar]

[CR137] 137.Kirk RA, Kesner RP, Wang LM, Wu Q, Towner RA, Hoffman JM, et al. Lipopolysaccharide exposure in a rat sepsis model results in hippocampal amyloid-beta plaque and phosphorylated tau deposition and corresponding behavioral deficits. Geroscience. 2019;41:467–481. doi: 10.1007/s11357-019-00089-9. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR138] 138.Lee JW, Lee YK, Yuk DY, Choi DY, Ban SB, Oh KW, et al. Neuro-inflammation induced by lipopolysaccharide causes cognitive impairment through enhancement of beta-amyloid generation. J Neuroinflammation. 2008;5:37. doi: 10.1186/1742-2094-5-37. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR139] 139.Wu Z, Ni J, Liu Y, Teeling JL, Takayama F, Collcutt A, et al. Cathepsin B plays a critical role in inducing Alzheimer's disease-like phenotypes following chronic systemic exposure to lipopolysaccharide from Porphyromonas gingivalis in mice. Brain Behav Immun. 2017;65:350–361. doi: 10.1016/j.bbi.2017.06.002. [DOI] [PubMed] [Google Scholar]

[CR140] 140.Deng X, Li M, Ai W, He L, Lu D, Patrylo PR, et al. Lipolysaccharide-induced neuroinflammation is associated with alzheimer-like amyloidogenic axonal pathology and dendritic degeneration in rats. Adv Alzheimer Dis. 2014;3:78–93. doi: 10.4236/aad.2014.32009. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR141] 141.Wang LM, Wu Q, Kirk RA, Horn KP, Ebada Salem AH, Hoffman JM, et al. Lipopolysaccharide endotoxemia induces amyloid-beta and p-tau formation in the rat brain. Am J Nucl Med Mol Imaging. 2018;8:86–99. [PMC free article] [PubMed] [Google Scholar]

[CR142] 142.Erickson MA, Hartvigson PE, Morofuji Y, Owen JB, Butterfield DA, Banks WA. Lipopolysaccharide impairs amyloid beta efflux from brain: altered vascular sequestration, cerebrospinal fluid reabsorption, peripheral clearance and transporter function at the blood-brain barrier. J Neuroinflammation. 2012;9:150. doi: 10.1186/1742-2094-9-150. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR143] 143.Sy M, Kitazawa M, Medeiros R, Whitman L, Cheng D, Lane TE, et al. Inflammation induced by infection potentiates tau pathological features in transgenic mice. Am J Pathol. 2011;178:2811–2822. doi: 10.1016/j.ajpath.2011.02.012. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR144] 144.Kitazawa M, Oddo S, Yamasaki TR, Green KN, LaFerla FM. Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J Neurosci. 2005;25:8843–8853. doi: 10.1523/JNEUROSCI.2868-05.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR145] 145.Bahar B, Singhrao SK. An evaluation of the molecular mode of action of trans-resveratrol in the Porphyromonas gingivalis lipopolysaccharide challenged neuronal cell model. Mol Biol Rep. 2021;48:147–156. doi: 10.1007/s11033-020-06024-y. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR146] 146.Liu J, Wang D, Li SQ, Yu Y, Ye RD. Suppression of LPS-induced tau hyperphosphorylation by serum amyloid A. J Neuroinflammation. 2016;13:28. doi: 10.1186/s12974-016-0493-y. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR147] 147.Roe AD, Staup MA, Serrats J, Sawchenko PE, Rissman RA. Lipopolysaccharide-induced tau phosphorylation and kinase activity–modulation, but not mediation, by corticotropin-releasing factor receptors. Eur J Neurosci. 2011;34:448–456. doi: 10.1111/j.1460-9568.2011.07764.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR148] 148.Barron M, Gartlon J, Dawson LA, Atkinson PJ, Pardon MC. A state of delirium: deciphering the effect of inflammation on tau pathology in Alzheimer's disease. Exp Gerontol. 2017;94:103–107. doi: 10.1016/j.exger.2016.12.006. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR149] 149.Rangasamy SB, Jana M, Roy A, Corbett GT, Kundu M, Chandra S, et al. Selective disruption of TLR2-MyD88 interaction inhibits inflammation and attenuates Alzheimer's pathology. J Clin Invest. 2018;128:4297–4312. doi: 10.1172/JCI96209. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR150] 150.Kim BW, Koppula S, Hong SS, Jeon SB, Kwon JH, Hwang BY, et al. Regulation of microglia activity by glaucocalyxin-A: attenuation of lipopolysaccharide-stimulated neuroinflammation through NF-kappaB and p38 MAPK signaling pathways. PLoS One. 2013;8:e55792. doi: 10.1371/journal.pone.0055792. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR151] 151.McCarthy GM, Bridges CR, Blednov YA, Harris RA. CNS cell-type localization and LPS response of TLR signaling pathways. F1000Res. 2017;6:1144. doi: 10.12688/f1000research.12036.1. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR152] 152.Mizobuchi H, Soma GI. Low-dose lipopolysaccharide as an immune regulator for homeostasis maintenance in the central nervous system through transformation to neuroprotective microglia. Neural Regen Res. 2021;16:1928–1934. doi: 10.4103/1673-5374.308067. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR153] 153.Jendresen C, Digre A, Cui H, Zhang X, Vlodavsky I, Li JP, et al. Systemic LPS-induced Abeta-solubilization and clearance in AbetaPP-transgenic mice is diminished by heparanase overexpression. Sci Rep. 2019;9:4600. doi: 10.1038/s41598-019-40999-4. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR154] 154.Go M, Kou J, Lim JE, Yang J, Fukuchi KI. Microglial response to LPS increases in wild-type mice during aging but diminishes in an Alzheimer's mouse model: implication of TLR4 signaling in disease progression. Biochem Biophys Res Commun. 2016;479:331–337. doi: 10.1016/j.bbrc.2016.09.073. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR155] 155.Quinn J, Montine T, Morrow J, Woodward WR, Kulhanek D, Eckenstein F. Inflammation and cerebral amyloidosis are disconnected in an animal model of Alzheimer's disease. J Neuroimmunol. 2003;137:32–41. doi: 10.1016/s0165-5728(03)00037-7. [DOI] [PubMed] [Google Scholar]

[CR156] 156.Thygesen C, Ilkjaer L, Kempf SJ, Hemdrup AL, von Linstow CU, Babcock AA, et al. Diverse protein profiles in CNS myeloid cells and CNS tissue from lipopolysaccharide- and vehicle-injected APPSWE/PS1DeltaE9 transgenic mice implicate Cathepsin Z in Alzheimer's disease. Front Cell Neurosci. 2018;12:397. doi: 10.3389/fncel.2018.00397. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR157] 157.Piao W, Song C, Chen H, Diaz MA, Wahl LM, Fitzgerald KA, et al. Endotoxin tolerance dysregulates MyD88- and Toll/IL-1R domain-containing adapter inducing IFN-beta-dependent pathways and increases expression of negative regulators of TLR signaling. J Leukoc Biol. 2009;86:863–875. doi: 10.1189/jlb.0309189. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR158] 158.Lee DC, Rizer J, Selenica ML, Reid P, Kraft C, Johnson A, et al. LPS- induced inflammation exacerbates phospho-tau pathology in rTg4510 mice. J Neuroinflammation. 2010;7:56. doi: 10.1186/1742-2094-7-56. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR159] 159.Zhou J, Yu W, Zhang M, Tian X, Li Y, Lu Y. Imbalance of microglial TLR4/TREM2 in LPS-treated APP/PS1 transgenic mice: a potential link between Alzheimer's disease and systemic inflammation. Neurochem Res. 2019;44:1138–1151. doi: 10.1007/s11064-019-02748-x. [DOI] [PubMed] [Google Scholar]

[CR160] 160.Drake L, Scott P. Investigation into RAGE as a biomarker of the LPS-induced murine model of neuroinflammation. J Nucl Med. 2019;60:480–480. [Google Scholar]

[CR161] 161.Cai Z, Liu N, Wang C, Qin B, Zhou Y, Xiao M, et al. Role of RAGE in Alzheimer's disease. Cell Mol Neurobiol. 2016;36:483–495. doi: 10.1007/s10571-015-0233-3. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR162] 162.Fang F, Lue LF, Yan S, Xu H, Luddy JS, Chen D, et al. RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease. FASEB J. 2010;24:1043–1055. doi: 10.1096/fj.09-139634. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR163] 163.Wang L, Wu J, Guo X, Huang X, Huang Q. RAGE plays a role in LPS-induced NF-kappaB activation and endothelial hyperpermeability. Sensors (Basel) 2017;17:722. doi: 10.3390/s17040722. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR164] 164.Loffredo L, Ettorre E, Zicari AM, Inghilleri M, Nocella C, Perri L, et al. Oxidative stress and gut-derived lipopolysaccharides in neurodegenerative disease: role of NOX2. Oxid Med Cell Longev. 2020;2020:8630275. doi: 10.1155/2020/8630275. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR165] 165.Zhang Y, Feng S, Nie K, Li Y, Gao Y, Gan R, et al. TREM2 modulates microglia phenotypes in the neuroinflammation of Parkinson's disease. Biochem Biophys Res Commun. 2018;499:797–802. doi: 10.1016/j.bbrc.2018.03.226. [DOI] [PubMed] [Google Scholar]

[CR166] 166.Kim S, Chung H, Ngoc Mai H, Nam Y, Shin SJ, Park YH, et al. Low-dose ionizing radiation modulates microglia phenotypes in the models of Alzheimer’s disease. Int J Mol Sci. 2020;21:4532. doi: 10.3390/ijms21124532. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR167] 167.Zhao J, Bi W, Xiao S, Lan X, Cheng X, Zhang J, et al. Neuroinflammation induced by lipopolysaccharide causes cognitive impairment in mice. Sci Rep. 2019;9:5790. doi: 10.1038/s41598-019-42286-8. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR168] 168.Sheppard O, Coleman MP, Durrant CS. Lipopolysaccharide-induced neuroinflammation induces presynaptic disruption through a direct action on brain tissue involving microglia-derived interleukin 1 beta. J Neuroinflammation. 2019;16:1–13. doi: 10.1186/s12974-019-1490-8. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR169] 169.Abareshi A, Anaeigoudari A, Norouzi F, Shafei MN, Boskabady MH, Khazaei M, et al. Lipopolysaccharide-induced spatial memory and synaptic plasticity impairment is preventable by captopril. Advances in medicine. 2016;2016:1–8. doi: 10.1155/2016/7676512. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR170] 170.Xin Y, Jiang J, Hu Y, Pan J, Mi X, Gao Q, et al. Immune system drives synapse loss during LPS-induced learning and memory impairment in mice. Front. Aging Neurosci. 2019;11:279. doi: 10.3389/fnagi.2019.00279. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR171] 171.Chugh D, Nilsson P, Afjei S-A, Bakochi A, Ekdahl CT. Brain inflammation induces post-synaptic changes during early synapse formation in adult-born hippocampal neurons. Exp Neurol. 2013;250:176–188. doi: 10.1016/j.expneurol.2013.09.005. [DOI] [PubMed] [Google Scholar]

[CR172] 172.Zhan X, Stamova B, Sharp FR. Lipopolysaccharide associates with amyloid plaques, neurons and oligodendrocytes in Alzheimer’s disease brain: a review. Front. Aging Neurosci. 2018;10:42. doi: 10.3389/fnagi.2018.00042. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR173] 173.Xing B, Bachstetter AD, Van Eldik LJ. Microglial p38α MAPK is critical for LPS-induced neuron degeneration, through a mechanism involving TNFα. Mol Neurodegener. 2011;6:1–12. doi: 10.1186/1750-1326-6-84. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR174] 174.Bachstetter AD, Xing B, de Almeida L, Dimayuga ER, Watterson DM, Van Eldik LJ. Microglial p38alpha MAPK is a key regulator of proinflammatory cytokine up-regulation induced by toll-like receptor (TLR) ligands or beta-amyloid (Abeta) J Neuroinflammation. 2011;8:79. doi: 10.1186/1742-2094-8-79. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR175] 175.Qin L, Liu Y, Hong JS, Crews FT. NADPH oxidase and aging drive microglial activation, oxidative stress, and dopaminergic neurodegeneration following systemic LPS administration. Glia. 2013;61:855–868. doi: 10.1002/glia.22479. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR176] 176.Ma MW, Wang J, Zhang Q, Wang R, Dhandapani KM, Vadlamudi RK, et al. NADPH oxidase in brain injury and neurodegenerative disorders. Mol Neurodegener. 2017;12:7. doi: 10.1186/s13024-017-0150-7. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR177] 177.Fragoso-Morales LG, Correa-Basurto J, Rosales-Hernandez MC. Implication of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and its inhibitors in Alzheimer's disease murine models. Antioxidants Basel. 2021;10:218. doi: 10.3390/antiox10020218. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR178] 178.Harland M, Torres S, Liu J, Wang X. Neuronal mitochondria modulation of LPS-induced neuroinflammation. J Neurosci. 2020;40:1756–1765. doi: 10.1523/JNEUROSCI.2324-19.2020. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR179] 179.Khan MS, Muhammad T, Ikram M, Kim MO. Dietary supplementation of the antioxidant curcumin halts systemic LPS-induced neuroinflammation-associated neurodegeneration and memory/synaptic impairment via the JNK/NF-kappaB/Akt signaling pathway in adult rats. Oxid Med Cell Longev. 2019;2019:7860650. doi: 10.1155/2019/7860650. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR180] 180.Li Y, Zhang L, Tang J, Yang X, Huang J, Zhu T, et al. Role of toll-like receptor 4 in the regulation of the cell death pathway and neuroinflammation. Brain Res Bull. 2019;148:79–90. doi: 10.1016/j.brainresbull.2019.03.015. [DOI] [PubMed] [Google Scholar]

[CR181] 181.Yang Y, Wang H, Kouadir M, Song H, Shi F. Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors. Cell Death Dis. 2019;10:1–11. doi: 10.1038/s41419-019-1413-8. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR182] 182.Calvo-Rodriguez M, García-Rodríguez C, Villalobos C, Núñez L. Role of toll like receptor 4 in Alzheimer’s disease. Front Immunol. 2020;11:1588. doi: 10.3389/fimmu.2020.01588. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR183] 183.Mattson M, Meffert M. Roles for NF-κB in nerve cell survival, plasticity, and disease. Cell Death Differ. 2006;13:852–860. doi: 10.1038/sj.cdd.4401837. [DOI] [PubMed] [Google Scholar]

[CR184] 184.Angelucci F, Cechova K, Amlerova J, Hort J. Antibiotics, gut microbiota, and Alzheimer’s disease. J Neuroinflammation. 2019;16:1–10. doi: 10.1186/s12974-019-1494-4. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR185] 185.Wang T, Hu X, Liang S, Li W, Wu X, Wang L, et al. Lactobacillus fermentum NS9 restores the antibiotic induced physiological and psychological abnormalities in rats. Benef Microbes. 2015;6:707–717. doi: 10.3920/BM2014.0177. [DOI] [PubMed] [Google Scholar]

[CR186] 186.Ribeiro CFA, Silveira G, Candido ES, Cardoso MH, Espinola Carvalho CM, Franco OL. Effects of antibiotic treatment on gut microbiota and how to overcome its negative impacts on human health. ACS Infect Dis. 2020;6:2544–2559. doi: 10.1021/acsinfecdis.0c00036. [DOI] [PubMed] [Google Scholar]

[CR187] 187.Balducci C, Santamaria G, La Vitola P, Brandi E, Grandi F, Viscomi AR, Beeg M, Gobbi M, Salmona M, Ottonello S, Forloni G. Doxycycline counteracts neuroinflammation restoring memory in Alzheimer's disease mouse models. Neurobiol Aging. 2018;70:128–139. doi: 10.1016/j.neurobiolaging.2018.06.002. [DOI] [PubMed] [Google Scholar]

[CR188] 188.Minter MR, Zhang C, Leone V, Ringus DL, Zhang X, Oyler-Castrillo P, Musch MW, Liao F, Ward JF, Holtzman DM, et al. Antibiotic-induced perturbations in gut microbial diversity influences neuro-inflammation and amyloidosis in a murine model of Alzheimer's disease. Sci Rep. 2016;6:30028. doi: 10.1038/srep30028. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR189] 189.Loeb MB, Molloy DW, Smieja M, Standish T, Goldsmith CH, Mahony J, Smith S, Borrie M, Decoteau E, Davidson W, et al. A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer's disease. J Am Geriatr Soc. 2004;52:381–387. doi: 10.1111/j.1532-5415.2004.52109.x. [DOI] [PubMed] [Google Scholar]

[CR190] 190.Rezaei Asl Z, Sepehri G, Salami M. Probiotic treatment improves the impaired spatial cognitive performance and restores synaptic plasticity in an animal model of Alzheimer's disease. Behav Brain Res. 2019;376:112183. doi: 10.1016/j.bbr.2019.112183. [DOI] [PubMed] [Google Scholar]

[CR191] 191.Abraham D, Feher J, Scuderi GL, Szabo D, Dobolyi A, Cservenak M, Juhasz J, Ligeti B, Pongor S, Gomez-Cabrera MC, et al. Exercise and probiotics attenuate the development of Alzheimer's disease in transgenic mice: role of microbiome. Exp Gerontol. 2019;115:122–131. doi: 10.1016/j.exger.2018.12.005. [DOI] [PubMed] [Google Scholar]

[CR192] 192.Nimgampalle M, Kuna Y. Anti-Alzheimer properties of probiotic, Lactobacillus plantarum MTCC 1325 in Alzheimer’s disease induced albino rats. J. Clin. Diagn. Res. JCDR. 2017;11:KC01. doi: 10.7860/JCDR/2017/26106.10428. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR193] 193.Akbari E, Asemi Z, Daneshvar Kakhaki R, Bahmani F, Kouchaki E, Tamtaji OR, Hamidi GA, Salami M. Effect of probiotic supplementation on cognitive function and metabolic status in Alzheimer's disease: a randomized, double-blind and controlled trial. Front Aging Neurosci. 2016;8:256. doi: 10.3389/fnagi.2016.00256. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR194] 194.Leblhuber F, Steiner K, Schuetz B, Fuchs D, Gostner JM. Probiotic supplementation in patients with Alzheimer's dementia-an explorative intervention study. Curr Alzheimer Res. 2018;15:1106–1113. doi: 10.2174/1389200219666180813144834. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR195] 195.Tamtaji OR, Heidari-Soureshjani R, Mirhosseini N, Kouchaki E, Bahmani F, Aghadavod E, Tajabadi-Ebrahimi M, Asemi Z. Probiotic and selenium co-supplementation, and the effects on clinical, metabolic and genetic status in Alzheimer's disease: a randomized, double-blind, controlled trial. Clin Nutr. 2019;38:2569–2575. doi: 10.1016/j.clnu.2018.11.034. [DOI] [PubMed] [Google Scholar]

[CR196] 196.Agahi A, Hamidi GA, Daneshvar R, Hamdieh M, Soheili M, Alinaghipour A, Esmaeili Taba SM, Salami M. Does severity of Alzheimer's disease contribute to its responsiveness to modifying gut microbiota? A double blind clinical trial. Front Neurol. 2018;9:662. doi: 10.3389/fneur.2018.00662. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR197] 197.Nagpal R, Neth BJ, Wang S, Mishra SP, Craft S, Yadav H. Gut mycobiome and its interaction with diet, gut bacteria and alzheimer's disease markers in subjects with mild cognitive impairment: A pilot study. EBioMedicine. 2020;59:102950. doi: 10.1016/j.ebiom.2020.102950. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR198] 198.Sun ZZ, Li XY, Wang S, Shen L, Ji HF. Bidirectional interactions between curcumin and gut microbiota in transgenic mice with Alzheimer's disease. Appl Microbiol Biotechnol. 2020;104:3507–3515. doi: 10.1007/s00253-020-10461-x. [DOI] [PubMed] [Google Scholar]

[CR199] 199.Park S, Kang S, Sol Kim D. Folate and vitamin B-12 deficiencies additively impaired memory function and disturbed the gut microbiota in amyloid-beta infused rats. Int J Vitam Nutr Res. 2019;1–13. [DOI] [PubMed]

[CR200] 200.Guo Y, Wang L, Lu J, Jiao J, Yang Y, Zhao H, et al. Ginsenoside Rg1 improves cognitive capability and affects the microbiota of large intestine of tree shrew model for Alzheimer's disease. Mol Med Rep. 2021;23:291. doi: 10.3892/mmr.2021.11931. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR201] 201.Bonfili L, Cecarini V, Berardi S, Scarpona S, Suchodolski JS, Nasuti C, et al. Microbiota modulation counteracts Alzheimer’s disease progression influencing neuronal proteolysis and gut hormones plasma levels. Sci Rep. 2017;7:1–21. doi: 10.1038/s41598-017-02587-2. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR202] 202.Kim MS, Kim Y, Choi H, Kim W, Park S, Lee D, Kim DK, Kim HJ, Choi H, Hyun DW, et al. Transfer of a healthy microbiota reduces amyloid and tau pathology in an Alzheimer's disease animal model. Gut. 2020;69:283–294. doi: 10.1136/gutjnl-2018-317431. [DOI] [PubMed] [Google Scholar]

[CR203] 203.Hazan S. Rapid improvement in Alzheimer's disease symptoms following fecal microbiota transplantation: a case report. J Int Med Res. 2020;48:300060520925930. doi: 10.1177/0300060520925930. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR204] 204.Dominy SS, Lynch C, Ermini F, Benedyk M, Marczyk A, Konradi A, Nguyen M, Haditsch U, Raha D, Griffin C. Porphyromonas gingivalis in Alzheimer’s disease brains: evidence for disease causation and treatment with small-molecule inhibitors. Sci. Adv. 2019;5:eaau3333. doi: 10.1126/sciadv.aau3333. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR205] 205.Wang H, Lee IS, Braun C, Enck P. Effect of probiotics on central nervous system functions in animals and humans: a systematic review. J Neurogastroenterol Motil. 2016;22:589–605. doi: 10.5056/jnm16018. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR206] 206.Wang T, Hu X, Liang S, Li W, Wu X, Wang L, Jin F. Lactobacillus fermentum NS9 restores the antibiotic induced physiological and psychological abnormalities in rats. Benef Microbes. 2015;6:707–717. doi: 10.3920/BM2014.0177. [DOI] [PubMed] [Google Scholar]

[CR207] 207.Chen D, Yang X, Yang J, Lai G, Yong T, Tang X, Shuai O, Zhou G, Xie Y, Wu Q. Prebiotic effect of fructooligosaccharides from Morinda officinalis on Alzheimer’s disease in rodent models by targeting the microbiota-gut-brain axis. Front. Aging Neurosci. 2017;9:403. doi: 10.3389/fnagi.2017.00403. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR208] 208.D'Argenio V, Sarnataro D. Microbiome influence in the pathogenesis of prion and Alzheimer's diseases. Int J Mol Sci. 2019;20:4704. doi: 10.3390/ijms20194704. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR209] 209.Shabbir U, Arshad MS, Sameen A, Oh DH. Crosstalk between gut and brain in Alzheimer's disease: the role of gut microbiota modulation strategies. Nutrients. 2021;13:690. doi: 10.3390/nu13020690. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR210] 210.Willett WC, Sacks F, Trichopoulou A, Drescher G, Ferro-Luzzi A, Helsing E, Trichopoulos D. Mediterranean diet pyramid: a cultural model for healthy eating. Am J Clin Nutr. 1995;61:1402S–1406S. doi: 10.1093/ajcn/61.6.1402S. [DOI] [PubMed] [Google Scholar]

[CR211] 211.Nagpal R, Neth BJ, Wang S, Craft S, Yadav H. Modified Mediterranean-ketogenic diet modulates gut microbiome and short-chain fatty acids in association with Alzheimer's disease markers in subjects with mild cognitive impairment. EBioMedicine. 2019;47:529–542. doi: 10.1016/j.ebiom.2019.08.032. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR212] 212.Costantini L, Molinari R, Farinon B, Merendino N. Impact of omega-3 fatty acids on the gut microbiota. Int J Mol Sci. 2017;18:2645. doi: 10.3390/ijms18122645. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR213] 213.La Rosa F, Clerici M, Ratto D, Occhinegro A, Licito A, Romeo M, Iorio CD, Rossi P. The gut-brain axis in Alzheimer's disease and omega-3. A critical overview of clinical trials. Nutrients. 2018;10:1267. doi: 10.3390/nu10091267. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR214] 214.Bonfili L, Cecarini V, Berardi S, Scarpona S, Suchodolski JS, Nasuti C, Fiorini D, Boarelli MC, Rossi G, Eleuteri AM. Microbiota modulation counteracts Alzheimer's disease progression influencing neuronal proteolysis and gut hormones plasma levels. Sci Rep. 2017;7:2426. doi: 10.1038/s41598-017-02587-2. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR215] 215.Kim M-S, Kim Y, Choi H, Kim W, Park S, Lee D, Kim DK, Kim HJ, Choi H, Hyun D-W. Transfer of a healthy microbiota reduces amyloid and tau pathology in an Alzheimer’s disease animal model. Gut. 2020;69:283–294. doi: 10.1136/gutjnl-2018-317431. [DOI] [PubMed] [Google Scholar]

[CR216] 216.Hazan S. Rapid improvement in Alzheimer’s disease symptoms following fecal microbiota transplantation: a case report. J Int Med Res. 2020;48:0300060520925930. doi: 10.1177/0300060520925930. [DOI] [PMC free article] [PubMed] [Google Scholar]

[CR217] 217.DeFilipp Z, Bloom PP, Torres Soto M, Mansour MK, Sater MRA, Huntley MH, Turbett S, Chung RT, Chen YB, Hohmann EL. Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant. N Engl J Med. 2019;381:2043–2050. doi: 10.1056/NEJMoa1910437. [DOI] [PubMed] [Google Scholar]

PERMALINK

Gram-negative bacteria and their lipopolysaccharides in Alzheimer’s disease: pathologic roles and therapeutic implications

Hyeon soo Kim

Sujin Kim

Soo Jung Shin

Yong Ho Park

Yunkwon Nam

Chae won Kim

Kang won Lee

Sung-Min Kim

In Duk Jung

Hyun Duk Yang

Yeong-Min Park

Minho Moon

Abstract

Supplementary Information

Introduction

Pathomechanisms of gram-negative bacteria in AD

Alteration of gram-negative bacteria in AD

Table 1.

Table 2.

Fig. 1.

Possible roles of gram-negative bacteria in AD pathogenesis

Microbiota dysbiosis

Aβ homeostasis

Fig. 2.

Table 3.

Tau pathology

Neuroinflammation

Neuronal cell death

Specific roles of LPS from gram-negative bacteria in AD

Peripheral and central localization of LPS in AD

Table 4.

Fig. 3.

Pathogenic contribution of LPS to AD-related pathology

Aβ homeostasis

Fig. 4.

Tau pathology

Neuroinflammation

Neurodegeneration

Gram-negative bacteria and their LPS as therapeutic targets in AD

Antibiotics for AD treatment

Table 5.

Gingipain inhibitor for AD treatment

Probiotics for AD treatment

Intestinal microbiota reconstruction for AD treatment

Conclusions

Supplementary Information

Acknowledgements

Abbreviations

Authors' contributions

Funding

Availability of data and materials

Declarations

Ethics approval and consent to participate

Consent for publication

Competing interests

Footnotes

Contributor Information

References

Associated Data

Supplementary Materials

Data Availability Statement

ACTIONS

PERMALINK

RESOURCES

Similar articles

Cited by other articles

Links to NCBI Databases